CA2561501A1 - Liquid cleansing composition with particulate optical modifiers - Google Patents
Liquid cleansing composition with particulate optical modifiers Download PDFInfo
- Publication number
- CA2561501A1 CA2561501A1 CA002561501A CA2561501A CA2561501A1 CA 2561501 A1 CA2561501 A1 CA 2561501A1 CA 002561501 A CA002561501 A CA 002561501A CA 2561501 A CA2561501 A CA 2561501A CA 2561501 A1 CA2561501 A1 CA 2561501A1
- Authority
- CA
- Canada
- Prior art keywords
- skin
- change
- composition according
- surfactant
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 232
- 230000003287 optical effect Effects 0.000 title claims abstract description 58
- 239000003607 modifier Substances 0.000 title claims abstract description 38
- 239000007788 liquid Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000007787 solid Substances 0.000 claims abstract description 26
- 238000000151 deposition Methods 0.000 claims abstract description 14
- 230000008859 change Effects 0.000 claims description 78
- 239000002245 particle Substances 0.000 claims description 65
- -1 alkyl fatty acid Chemical class 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000004094 surface-active agent Substances 0.000 claims description 37
- 230000000007 visual effect Effects 0.000 claims description 30
- 229920000642 polymer Polymers 0.000 claims description 28
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000003974 emollient agent Substances 0.000 claims description 25
- 241000282372 Panthera onca Species 0.000 claims description 23
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000011156 evaluation Methods 0.000 claims description 21
- 229910052618 mica group Inorganic materials 0.000 claims description 21
- 239000003921 oil Substances 0.000 claims description 21
- 125000002091 cationic group Chemical group 0.000 claims description 20
- 239000010445 mica Substances 0.000 claims description 20
- 241000276425 Xiphophorus maculatus Species 0.000 claims description 17
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002280 amphoteric surfactant Substances 0.000 claims description 16
- 239000003945 anionic surfactant Substances 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 229960003237 betaine Drugs 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 14
- 125000000129 anionic group Chemical group 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 229920006317 cationic polymer Polymers 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- 235000019271 petrolatum Nutrition 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000003093 cationic surfactant Substances 0.000 claims description 9
- 230000008021 deposition Effects 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 239000002736 nonionic surfactant Substances 0.000 claims description 9
- 238000002310 reflectometry Methods 0.000 claims description 9
- 239000004264 Petrolatum Substances 0.000 claims description 8
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical group C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 229940066842 petrolatum Drugs 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 229920001519 homopolymer Polymers 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102220549062 Low molecular weight phosphotyrosine protein phosphatase_C13S_mutation Human genes 0.000 claims description 6
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 6
- 229940073609 bismuth oxychloride Drugs 0.000 claims description 6
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 claims description 6
- 150000003445 sucroses Chemical class 0.000 claims description 6
- 239000001993 wax Substances 0.000 claims description 6
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 5
- 206010040829 Skin discolouration Diseases 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 4
- 244000060011 Cocos nucifera Species 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000037311 normal skin Effects 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- IZWSFJTYBVKZNK-UHFFFAOYSA-O N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonic acid Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS(O)(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-O 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 2
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 claims description 2
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 229910000423 chromium oxide Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 239000011147 inorganic material Substances 0.000 claims description 2
- 239000001023 inorganic pigment Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000011368 organic material Substances 0.000 claims description 2
- 239000012860 organic pigment Substances 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 230000000063 preceeding effect Effects 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 229940057400 trihydroxystearin Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229940097407 palm kernel acid Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 80
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical group C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- 239000000693 micelle Substances 0.000 description 14
- 239000003205 fragrance Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 229960005196 titanium dioxide Drugs 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000004408 titanium dioxide Substances 0.000 description 7
- 235000010215 titanium dioxide Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000004927 clay Substances 0.000 description 6
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 6
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 5
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 244000000231 Sesamum indicum Species 0.000 description 3
- 206010040799 Skin atrophy Diseases 0.000 description 3
- 241001135917 Vitellaria paradoxa Species 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000004533 oil dispersion Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 229940057910 shea butter Drugs 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- PIORTDHJOLELKR-UHFFFAOYSA-N 2,4-dichloro-1-(4-chlorophenoxy)benzene Chemical compound C1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl PIORTDHJOLELKR-UHFFFAOYSA-N 0.000 description 2
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 2
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910000906 Bronze Inorganic materials 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 240000008669 Hedera helix Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000047703 Nonion Species 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000008673 Persea americana Nutrition 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229940122511 Sebum inhibitor Drugs 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000010974 bronze Substances 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- VEVFSWCSRVJBSM-HOFKKMOUSA-N ethyl 4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 VEVFSWCSRVJBSM-HOFKKMOUSA-N 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940055390 glycerin / propylene glycol Drugs 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229940067631 phospholipid Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical class OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- NSSALFVIQPAIQK-FPLPWBNLSA-N (Z)-2-Nonen-1-ol Chemical compound CCCCCC\C=C/CO NSSALFVIQPAIQK-FPLPWBNLSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- KNUPSOXBESCJLY-UHFFFAOYSA-N 2-methoxy-1-phenylhexan-1-one Chemical compound CCCCC(OC)C(=O)C1=CC=CC=C1 KNUPSOXBESCJLY-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BHVJSLPLFOAMEV-UHIFYLTQSA-M 20-Epibryonolic acid Natural products C([C@H]1[C@]2(C)CC3)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@]2(C)C1=C3[C@@]2(C)CC[C@H](O)C(C)(C)[C@@H]2CC1 BHVJSLPLFOAMEV-UHIFYLTQSA-M 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- BHVJSLPLFOAMEV-UHFFFAOYSA-N Bryonolic acid Natural products C1CC2(C)C3CC(C)(C(O)=O)CCC3(C)CCC2(C)C2=C1C1(C)CCC(O)C(C)(C)C1CC2 BHVJSLPLFOAMEV-UHFFFAOYSA-N 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- DSEKYWAQQVUQTP-UHFFFAOYSA-N Cerin Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CC(O)C(=O)C2C DSEKYWAQQVUQTP-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000016904 Citrus x jambhiri Nutrition 0.000 description 1
- 244000114646 Citrus x jambhiri Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001251094 Formica Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 240000004282 Grewia occidentalis Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 235000008418 Hedeoma Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001243942 Isotropis Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003347 Microthene® Polymers 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 101000721481 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Succinyl-diaminopimelate desuccinylase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- NNCOOIBIVIODKO-UHFFFAOYSA-N aluminum;hypochlorous acid Chemical compound [Al].ClO NNCOOIBIVIODKO-UHFFFAOYSA-N 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- ZCILODAAHLISPY-UHFFFAOYSA-N biphenyl ether Natural products C1=C(CC=C)C(O)=CC(OC=2C(=CC(CC=C)=CC=2)O)=C1 ZCILODAAHLISPY-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- SBBWEQLNKVHYCX-UHFFFAOYSA-N ethyl 2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)C(N)CC1=CC=C(O)C=C1 SBBWEQLNKVHYCX-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940031726 laureth-10 Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PJFGPJQBWSEWKX-UHFFFAOYSA-N n-[(2,4-dichlorophenoxy)-methoxyphosphinothioyl]propan-2-amine Chemical compound CC(C)NP(=S)(OC)OC1=CC=C(Cl)C=C1Cl PJFGPJQBWSEWKX-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/03—Liquid compositions with two or more distinct layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
- A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
Abstract
A liquid cleansing composition is disclosed that contains a solid particulate optical modifier that modifies the appearance of the skin after rinsing the skin. A method of depositing the solid particulate optical modifier to the skin or hair with the cleansing composition is also disclosed.
Description
LIQUID CLEANSING COMPOSITION WITH PARTICULATE OPTICAL
'ARI1T TT1T'L1'L7 C'~
The present invention relates to detergent compositions suitable for topical application for cleansing the human body, such as the skin and hair. In particular, it relates to compositions containing particulate optical modifiers) that change the appearance of the skin after wash off.
The visual appearance of skin is normally changed by using personal care compositions that are left on the skin.
However, it would be useful if the visual appearance of skin could also be changed by using cleansing compositions that are washed off the skin. Such products would be beneficial to consumers who are looking for multiple functionalities in their cleansing products, such as cleansers that simultaneously cleanse and moisturize.
In this case, products that cleanse the skin will also make it shine, sparkle, or glow by leaving behind solid particles that affect the interaction of light with the skin. These cleansers would save consumers the time required to apply a leave-on product that will change the visual appearance of the skin, and will also give them the benefit of appearing more attractive. Optionally, these cleansers could also contain moisturizers and emollients to condition the skin, and one or more active agents which can be used to deliver a benefit to the skin and which generally are not used to confer a conditioning benefit.
_ 2 _ Prior art skin cleansers modify the way the skin feel s after the shower by depositing materials such as oils or polymers.
Such materials deposit on the skin by various mechanisms, including attraction of cationic materials to the anionic surface of the skin. However, materials that change the feel of the skin do not generally change the look of the skin.
Surprisingly it has been discovered that by incorporating certain solid particles and a specific cationic polymer in a cleanser formulation, the visual appearance of the sh in can be modified after wash off without the need for a complex delivery system employing specific oil droplets.
U.S. Patent no. 6395691 issued to Tsaur on May 28, 2002 directed to a personal wash liquid formulation discloses the use of a particle-in-oil dispersion to deliver solid particles to the skin that are effected by adjusting the size of the oil droplet and the size ratio between th a oil droplet and the particles, and employs large droplets of petrolatum or thickened oil to deposit particles. Th a composition of Tsaur contains 2 o to 20 o by wt. of such a particle-in-oil dispersion.
In a co-pending U.S. patent application S/N 10/443396 filed ~25 on May 22, 2003 by Zhang et al. relating to the deposition of particles from a cleanser, the particles being deposited are small (under 20 microns), and the formulations disclosed rely on structured oil to deposit the particles. In anoth a r co-pending U.S. patent application S/N 10/241401 filed o n Sept.
11, 2002 by Zhang et al. relating to the deposition of particles from a cleanser, the particles being deposit ed have a specified geometry and refractive index, and the formulations disclosed re 1y on a particle-in-oil dispersion to deposit the particles.
Cosmetic formulations tha t are left on the skin and contain solid particles to modify the skin appearance are well known.
For example, many current 1y available lotions. contain mica coated with titanium diox zde or iron oxide that make the s1 in sparkle. Wash-off cleanser formulations that contain solid particles to modify the appearance of the cleanser itself a re~
also well known. For example, many currently available body wash products contain mic a coated with titanium dioxide to give the product a shimmering appearance. In addition, cleanser formulations may contain solid particles to give t he formulation abrasive char acteristics and to exfoliate the skin. Many products that are marketed as exfoliating cleansers contain particles such as polyethylene or various fruit seeds to scrub the s kin.
US Publication no. X003/0134759 A1 published on July 17, 2003 to Geary et al. describes a formulation that contains surfactant, water-insolub Z a solid particles, a synthetic cationic polymer, and a phase separation initiator and whic h contains from 0.025 o to 5o by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and a n average molecular weight of from 1,000 to 5,000,000. The solid particles are depos.zted when the phase separation initiator causes the polymer to form a liquid crystal phase.
In a first aspect of the invention there is provided a liquid cleansing composition comp rising:
(a) 1 % to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphot eric or cationic surfactant or mixtures tl-sereof;
(b) 0.1 o to 10 0 of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Vales Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical prop erties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below.
In a further aspect of the invents on there is provided a method of depositing a solid part-~culate optical modifier onto the skin from a liquid cleans ing composition comprising:
(a) 1 o to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphot eric or cationic surfactant or mixtures tl-sereof;
(b) 0.1 o to 10 0 of a catiorsic polymer;
(c) an effective concentrate~n of a solid particulate optical modifier for exhi biting a specific set of optical properties on ski n characterized by a set of Tristimulus Color Vales L,, a*, and b*; a reflectivity change, and a n opacity change, that provides at least a 5 % change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below;
(d) applying said cleansing composition to the skin or hair; and (e) rinsing off said cleansing composition.
In a further aspect of the inventio n is a liquid cleansing composition comprising:
(a) 1 % to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereofy (b) 0.1 o to 10 0 of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical properties when said cleansing composition is applied to s kin and then rinsed off using the In-vitro Visual .assessment Protocol.
In a preferred embodiment of this a spent of the invention, the inventive composition further comprises:
(a) a thickening agent;
(b) wherein the viscosity of the cleansing composition is in the range of 1,000 to 300,000 cps, preferably 5, 000 to 50, 000 cps @ 1/sec shear rate a-t 25°C using the cone and plate method described below; and, (c) wherein the cleansing composition is iso t Topic.
In a second preferred embodiment of this aspect a f the invention, the inventive cleansing composition further comprises:
(a) 3 o to 30 o by weight of a surfactant sy stem including at least one surfactant select a d from an anionic, amphoteric, cationic and nonion z c surfactant and mixtures thereof, wherein at least one anionic surfactant must be present;
(b) 0.1 o to 15 % by wt. of an ordered liqui d crystalline phase inducing structurant f or inducing an ordered liquid crystalline phase in s aid cleansing composition; preferably wherein the ordered liquid crystalline phase inducin g structurant is selected from a C8 to C24 alkenyl or branched alkyl fatty acid or ester there of, a C8 to C24 alkenyl or branched alkyl alcohol or ether thereof, a C5 to C14 linear alkyl fatty acid, trihydroxystearin, or derivatives or mix t ures thereof: more preferably wherein the ord eyed liquid crystalline phase inducing structurant i s selected from lauric acid, oleic acid, palm kerne 1 acid, palm fatty acid, coconut acid, isosteari c acid, or derivatives or mixtures thereof; and st ill more preferably wherein the ordered liquid crystalline phase has lamellar structure;
(c) wherein said ordered liquid crystalline phase composition has a viscosity of 40,000 to 300,000 cps at 25°C as measured via the T-bar method; and (d) wherein said ordered liquid crystall.zne phase composition contains less than 0.025 o by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and an average molecular weight of from 1,000 to 5,000,000. Preferably the inventive ordered liquid crystalline phase composition contains 0 0 of this polymer.
Preferably the visual attribute targeted by the optical modifier is selected from skin shine, skin color or skin optical uniformity, and combinations thereof. These attributes can be further estimated by way of h value, reflectance change and opacity change using the In-vitro Visual Assessment~Protocol described below.
Advantageously the change in L value is in th a range from 0 to +10, the reflectance change is in the rang a from 0 to +300 0, and the change in opacity is in the range from 0 to +20 o with the proviso that the change in L v aloe, reflectance change and opacity change are not all zero so as to provide noticeable skin shine when said cleansing composition is applied to skin and then rinse d off using the In-vitro Visual Assessment Protocol; preferab 1 y wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0 ) of the pa rticulate _ g _ optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of= 1.8 to 4.0;
ii) the geometry is platy, cylindrical or a blend thereof; and iii) the specific dimensions are 10 to 200 um average diameter in the case of a platy particle, or 10 to 200 um in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle.
Advantageously the change in Z value is in the range from 0 to +10, the change in the a* value is in the range from 0 to +10, the change in the b* value is in the range from 0 t o +10, the change in opacity is in the range from 0 to +50 0, and the reflectance change is within the normal skin reflectivity range of +10 0, with the proviso that the change in Z value, b* and opacity change are not all zer o so as to provide noticeable skin lightening or color change when said cleansing composition is applied to skin and t hen rinsed off using the In-vitro Visual Assessment Protocol;
preferably wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0) of the particulate optical modifier is further defined I~y an exterior surface refractive index, geometry, and specifi c dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 4.0;
ii) the geometry is spheroidal, platy or a blend thereof;
iii) the specific dimensions are 1 to 30um average diameter in the case of a platy particle, or 0.1 to 1 um in average diameter in the case of a spheroidal particle; and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
Advantageously the change in Z value is in the range from 0 to +5, the reflectance change is in the range from 0 to +100 o, the change in opacity is in the range from 0 to +50 0, and the change in a* and b* are within normal skin color range of +10 o for each of a* or b*, with the proviso that the change in Z value, reflectance change and opacity change are not all zero so as to provide noticeable skin optical uniformity change when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol: preferably wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0) of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 2.0 ii) the geometry is spheroidal, platy, cylindrical or a blend thereof iii) the specific dimensions are 0.1 to 200 um in average diameter in the case of a spheroidal particle, 1 to 10 um average diameter in the case of a platy particle, or 1 to 10 um in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle, and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
In a further preferred embodiment of the inventive cleansing composition, the particulate optical modifier is composed predominately of platy particles further defined by having an average plate diameter of 10 pm to 200 um and a refractive index of at least 1.8 (preferably having an average plate diameter of about 10 um to 100 ~Zm and a refractive index of at least about 2); and more preferably wherein the particulate optical modifier contains a surface modification selected from amino acids, proteins, fatty acids, lipids, phospholipids (lecithin), anionic and/or cationic oligomers/polymers or blends or derivatives thereof to enhance the deposition of the optical modifier on to the skin.
Preferably the inventive composition contains a cationic polymer having a charge density of at least 0.7 Meq/g (more preferably at least about 0.8, 0.9 or 1.0 Meq/g); still more preferably wherein the cationic polymer is selected from Merquat~ 100 or 2200, Jaguars C17 or C13S, Salcare~ Supre 7, SC10, or SC30; Gafquat ~ HS100 or 755, and Luviquat~
FC370, FC550, HM552 or FC905; or blends thereof.
Advantageously the inventive composition contains an anionic surfactant and optionally an amphoteric surfactant, preferably wherein the anionic surfactant is selected from a C8-C16 alkyl sulfate and/or alkyl ether sulfates, fatty acid soaps, taurates, sulfosuccinates, glycinates, sarcosinates or blends thereof and the amphoteric surfactant is selected from amphoacetates, betaines and amidoalkyl betaines or derivatives or blends thereof.
Advantageously the ratio of anionic surfactant to a surfactant that has a positive charge at a pH of 6.5 or below (preferably where the surfactant has a positive charge at a pH of about 5.5 or below) is in the range of 15:1 to 1:2; in the case of the isotropic composition and is in the range of about 6:1 to about 1:2 in the case of the liquid crystalline structured composition. Preferably wherein the surfactant with the positive charge is an amphoteric surfactant; and more preferably wherein the amphoteric surfactant is selected from betaine, alkylamidopropyl betaine, sulphobetaine, amphoacetate or blends thereof.
In a further preferred embodiment, the solid particulate optical modifier has an average diameter of at least 30 microns (preferably at least about 40, 50, 60, 70, 80, 90, 100, 120, 140, or 150 microns). Preferably the solid particulate optical modifier is present in a minimum concentration of at least 0.2 o by wt. (preferably at least about 0.25, 0.3, 0.4, 0.5, 0.7, 0.~, or 1 o by wt.).
Advantageously the thickening agent for the isotropic composition is selected from polyacrylates; silica; natural and synthetic waxes; aluminum silicate; lanolin derivatives;
C8 to C20 fatty alcohols polyethylene copolymers;
polyammonium carboxylates: sucrose esters; hydrophobic clays; petrolatum; hydrotalcites; cellulose derivatives, polysaccharide derivatives, or derivatives and mixtures thereof. Preferably the isotropic composition is structured with a structurant selected from swelling clays; cross-linked polyacrylates; acrylate homopolymers and copolymers;
polyvinylpyrrolidone homopolymers and copolymers;
polyethylene imines: inorganic salts; sucrose esters, gellants or blends and derivatives thereof.
Advantageously the inventive isotropic structured composition further comprises an emollient having a weight average emollient particle size in the range of 1 to 500 microns; preferably wherein the composition contains less than 10 o by wt. of hydrophobic emollient(s).
More preferably, the isotropic composition has less than 50 o by wt. (preferably less than about 40, 30, 20, 10, or 5 0 by wt.) of the solid particulate optical modifier suspended in an oil. Preferably the isotropic composition contains less than about 10 % by wt. (preferably less than 5, 2, 1, 0.5, 0.1 or 0.05 o by wt.) of hydrophobic emollients) (as defined below) .
In a further preferred embodiment the composition contains at least 7 wt o; preferably 10 to 25 wt o of the surfactant, and preferably the particulate optical modifier is selected from organic pigments, inorganic pigments, polymers, titanium oxide, zinc oxide, colored iron oxide, chromium oxide/hydroxide/hydrate, alumina, silica, zirconia, barium sulfate, silicates, polyethylene, polypropylene, nylon, ultramarine, alkaline earth carbonates, talc, sericite, mica, synthetic mica, polymers, platy substrate coated with organic and inorganic materials, bismuth oxychloride, barium sulfate, or blends and physical aggregates thereof; more preferably wherein the particulate optical modifier pons esses color generated through fluorescence, adsorption, iridescence or a combination thereof. Preferably the inventive composition comprises greater than 30 % by weight water .
In a further aspect of the invention is provided a method of depositing a solid particulate optical modifier onto the skin from a liquid cleansing composition according to any of the preceeding claims, or a blend thereof, comprising the steps of (a) 1 o to 35 wt. o of surfactants) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereof;
(b) 0.1 o to 10 0 of a cationic polymer;
(c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below;
(d) applying said cleansing composition to the skin or hair; and (e) rinsing off said cleansing composition.
Surfactants are an essential component of the inventive cleansing composition. They are compounds that have hydrophobic and hydrophilic portions that act to reduce the surface tension of the aqueous solutions they are dissolved in. Useful surfactants can include anionic, nonionic, amphoteric, and cationic surfactants,, and blends thereof.
The cleansing composition of the present invention may contain one or more anionic detergents. Anionic surfactants are preferably used at levels as low as 3 or 5 or 7 o by wt., and at levels as high as 12 or 15 o by wt.
The anionic detergent active which may be used may be aliphatic sulfonates, such as a primary alkane (e.g., Cg-C~~) sulf onate, primary alkane (e.g., Cg-C2~) disulfonate, Cg-C~~
alkene sulfonate, Cg-C22 hydroxyalkane sulfonate or alkyl glyceryl ether sulfonate (AGS); or aromatic sulfonates such as alkyl benzene sulfonate.
The anionic may also be an alkyl sulfate (e. g., C12-C1g alkyl sulfate) or an alkyl ether sulfate (including alkyl glyceryl ether sulfates). Among the alkyl ether sulfates are those having the formula:
RO(CH2CH20)nS03M
wherein R is an alkyl or alkenyl having 8 to 18 carbons, preferably 12 to 18 carbons, n has an average value of greater than 1.0, preferably greater than 3; and M is a solubilizing cat s on such as sodium, potassium, ammonium or substituted ammonium. Ammonium and sodium lauryl ether sulfates are preferred.
The anionic may also be alkyl sulfosuccinates (including mono- and dialkyl, e.g., C6-C~2 sulfosuccinates); alkyl and acyl taurates, a 1 kyl and acyl sarcosinates, sulfoacetates, Cg-C2~ alkyl phosphates and phosphates, alkyl phosphate esters and alkoxyl alkyl phosphate esters, acyl lactates, Cg-C22 monoalkyl succin ates and maleates, sulphoacetates, alkyl glucosides and a cyl isethionates, and the like.
Sulfosuccinates rnay be monoalkyl sulfosuccinates having the formula:
R 40~CCH~CH(S03M)C02M; and amide-MEA sulfosuccinates of the formula;
R~CONHCH2CH202CCH~CH(S03M)CO~M
wherein R4 range s from Cg-C22 alkyl and M is a solubilizing cation.
Sarcosinates are generally indicated by the formula:
R~CON(CH3)CH2CO~M, wherein R1 ranges from Cg-C2p alkyl and M is a solubilizing canon.
Taurates are generally identified by formula:
R2CONR3CH2CH~S03M
wherein R~ ranges from Cg-C2p alkyl, R3 ranges from C1-C4 alkyl and M is a solubilizing ration.
The inventive cleansing composition may contain Cg-Clg aryl isethionates. These esters are prepared by reaction between alkali metal isethionate with mixed aliphatic fatty acids having from 6 to 18 carbon atoms and an iodine value of less than 20. At least 75 0 of the mixed fatty acids have from 12 to 18 carbon atoms and up to 25 o have from 6 to 10 carbon atoms.
The aryl isethionate may be an alkoxylated isethionate such as is described in Ilardi et al., U.S. Patent No. 5,393,466, titled "Fatty Acid Esters of Polyalkoxylated isethonic acid°', issued February 28, 1995; hereby incorporated by reference.
This compound has the general formula:
I I
R C-0-CH-CH2-(0CH-CH2)m-S03M
wherein R is an alkyl group having 8 to 18 carbons, m is an integer from 1 to 4, X and Y are hydrogen or an alkyl group having 1 to 4 carbons and M+ is a monovalent cation such as, for example, sodium, potassium or ammonium.
One or more amphoteric surfactants may be used in this invention. Amphoteric surfactants are preferably used at levels as low as 0.5 or 0.8 0, and at levels as high as 4 or 5 o by wt. for isotropic compostions or levels as low as 1 or
'ARI1T TT1T'L1'L7 C'~
The present invention relates to detergent compositions suitable for topical application for cleansing the human body, such as the skin and hair. In particular, it relates to compositions containing particulate optical modifiers) that change the appearance of the skin after wash off.
The visual appearance of skin is normally changed by using personal care compositions that are left on the skin.
However, it would be useful if the visual appearance of skin could also be changed by using cleansing compositions that are washed off the skin. Such products would be beneficial to consumers who are looking for multiple functionalities in their cleansing products, such as cleansers that simultaneously cleanse and moisturize.
In this case, products that cleanse the skin will also make it shine, sparkle, or glow by leaving behind solid particles that affect the interaction of light with the skin. These cleansers would save consumers the time required to apply a leave-on product that will change the visual appearance of the skin, and will also give them the benefit of appearing more attractive. Optionally, these cleansers could also contain moisturizers and emollients to condition the skin, and one or more active agents which can be used to deliver a benefit to the skin and which generally are not used to confer a conditioning benefit.
_ 2 _ Prior art skin cleansers modify the way the skin feel s after the shower by depositing materials such as oils or polymers.
Such materials deposit on the skin by various mechanisms, including attraction of cationic materials to the anionic surface of the skin. However, materials that change the feel of the skin do not generally change the look of the skin.
Surprisingly it has been discovered that by incorporating certain solid particles and a specific cationic polymer in a cleanser formulation, the visual appearance of the sh in can be modified after wash off without the need for a complex delivery system employing specific oil droplets.
U.S. Patent no. 6395691 issued to Tsaur on May 28, 2002 directed to a personal wash liquid formulation discloses the use of a particle-in-oil dispersion to deliver solid particles to the skin that are effected by adjusting the size of the oil droplet and the size ratio between th a oil droplet and the particles, and employs large droplets of petrolatum or thickened oil to deposit particles. Th a composition of Tsaur contains 2 o to 20 o by wt. of such a particle-in-oil dispersion.
In a co-pending U.S. patent application S/N 10/443396 filed ~25 on May 22, 2003 by Zhang et al. relating to the deposition of particles from a cleanser, the particles being deposited are small (under 20 microns), and the formulations disclosed rely on structured oil to deposit the particles. In anoth a r co-pending U.S. patent application S/N 10/241401 filed o n Sept.
11, 2002 by Zhang et al. relating to the deposition of particles from a cleanser, the particles being deposit ed have a specified geometry and refractive index, and the formulations disclosed re 1y on a particle-in-oil dispersion to deposit the particles.
Cosmetic formulations tha t are left on the skin and contain solid particles to modify the skin appearance are well known.
For example, many current 1y available lotions. contain mica coated with titanium diox zde or iron oxide that make the s1 in sparkle. Wash-off cleanser formulations that contain solid particles to modify the appearance of the cleanser itself a re~
also well known. For example, many currently available body wash products contain mic a coated with titanium dioxide to give the product a shimmering appearance. In addition, cleanser formulations may contain solid particles to give t he formulation abrasive char acteristics and to exfoliate the skin. Many products that are marketed as exfoliating cleansers contain particles such as polyethylene or various fruit seeds to scrub the s kin.
US Publication no. X003/0134759 A1 published on July 17, 2003 to Geary et al. describes a formulation that contains surfactant, water-insolub Z a solid particles, a synthetic cationic polymer, and a phase separation initiator and whic h contains from 0.025 o to 5o by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and a n average molecular weight of from 1,000 to 5,000,000. The solid particles are depos.zted when the phase separation initiator causes the polymer to form a liquid crystal phase.
In a first aspect of the invention there is provided a liquid cleansing composition comp rising:
(a) 1 % to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphot eric or cationic surfactant or mixtures tl-sereof;
(b) 0.1 o to 10 0 of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Vales Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical prop erties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below.
In a further aspect of the invents on there is provided a method of depositing a solid part-~culate optical modifier onto the skin from a liquid cleans ing composition comprising:
(a) 1 o to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphot eric or cationic surfactant or mixtures tl-sereof;
(b) 0.1 o to 10 0 of a catiorsic polymer;
(c) an effective concentrate~n of a solid particulate optical modifier for exhi biting a specific set of optical properties on ski n characterized by a set of Tristimulus Color Vales L,, a*, and b*; a reflectivity change, and a n opacity change, that provides at least a 5 % change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below;
(d) applying said cleansing composition to the skin or hair; and (e) rinsing off said cleansing composition.
In a further aspect of the inventio n is a liquid cleansing composition comprising:
(a) 1 % to 35 wt. o of surfactant (s) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereofy (b) 0.1 o to 10 0 of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical properties when said cleansing composition is applied to s kin and then rinsed off using the In-vitro Visual .assessment Protocol.
In a preferred embodiment of this a spent of the invention, the inventive composition further comprises:
(a) a thickening agent;
(b) wherein the viscosity of the cleansing composition is in the range of 1,000 to 300,000 cps, preferably 5, 000 to 50, 000 cps @ 1/sec shear rate a-t 25°C using the cone and plate method described below; and, (c) wherein the cleansing composition is iso t Topic.
In a second preferred embodiment of this aspect a f the invention, the inventive cleansing composition further comprises:
(a) 3 o to 30 o by weight of a surfactant sy stem including at least one surfactant select a d from an anionic, amphoteric, cationic and nonion z c surfactant and mixtures thereof, wherein at least one anionic surfactant must be present;
(b) 0.1 o to 15 % by wt. of an ordered liqui d crystalline phase inducing structurant f or inducing an ordered liquid crystalline phase in s aid cleansing composition; preferably wherein the ordered liquid crystalline phase inducin g structurant is selected from a C8 to C24 alkenyl or branched alkyl fatty acid or ester there of, a C8 to C24 alkenyl or branched alkyl alcohol or ether thereof, a C5 to C14 linear alkyl fatty acid, trihydroxystearin, or derivatives or mix t ures thereof: more preferably wherein the ord eyed liquid crystalline phase inducing structurant i s selected from lauric acid, oleic acid, palm kerne 1 acid, palm fatty acid, coconut acid, isosteari c acid, or derivatives or mixtures thereof; and st ill more preferably wherein the ordered liquid crystalline phase has lamellar structure;
(c) wherein said ordered liquid crystalline phase composition has a viscosity of 40,000 to 300,000 cps at 25°C as measured via the T-bar method; and (d) wherein said ordered liquid crystall.zne phase composition contains less than 0.025 o by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and an average molecular weight of from 1,000 to 5,000,000. Preferably the inventive ordered liquid crystalline phase composition contains 0 0 of this polymer.
Preferably the visual attribute targeted by the optical modifier is selected from skin shine, skin color or skin optical uniformity, and combinations thereof. These attributes can be further estimated by way of h value, reflectance change and opacity change using the In-vitro Visual Assessment~Protocol described below.
Advantageously the change in L value is in th a range from 0 to +10, the reflectance change is in the rang a from 0 to +300 0, and the change in opacity is in the range from 0 to +20 o with the proviso that the change in L v aloe, reflectance change and opacity change are not all zero so as to provide noticeable skin shine when said cleansing composition is applied to skin and then rinse d off using the In-vitro Visual Assessment Protocol; preferab 1 y wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0 ) of the pa rticulate _ g _ optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of= 1.8 to 4.0;
ii) the geometry is platy, cylindrical or a blend thereof; and iii) the specific dimensions are 10 to 200 um average diameter in the case of a platy particle, or 10 to 200 um in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle.
Advantageously the change in Z value is in the range from 0 to +10, the change in the a* value is in the range from 0 to +10, the change in the b* value is in the range from 0 t o +10, the change in opacity is in the range from 0 to +50 0, and the reflectance change is within the normal skin reflectivity range of +10 0, with the proviso that the change in Z value, b* and opacity change are not all zer o so as to provide noticeable skin lightening or color change when said cleansing composition is applied to skin and t hen rinsed off using the In-vitro Visual Assessment Protocol;
preferably wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0) of the particulate optical modifier is further defined I~y an exterior surface refractive index, geometry, and specifi c dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 4.0;
ii) the geometry is spheroidal, platy or a blend thereof;
iii) the specific dimensions are 1 to 30um average diameter in the case of a platy particle, or 0.1 to 1 um in average diameter in the case of a spheroidal particle; and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
Advantageously the change in Z value is in the range from 0 to +5, the reflectance change is in the range from 0 to +100 o, the change in opacity is in the range from 0 to +50 0, and the change in a* and b* are within normal skin color range of +10 o for each of a* or b*, with the proviso that the change in Z value, reflectance change and opacity change are not all zero so as to provide noticeable skin optical uniformity change when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol: preferably wherein greater than 10 o by wt. (preferably greater than about 20, 30, 40, 50, 60, 70, 80, 90 or 95 0) of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 2.0 ii) the geometry is spheroidal, platy, cylindrical or a blend thereof iii) the specific dimensions are 0.1 to 200 um in average diameter in the case of a spheroidal particle, 1 to 10 um average diameter in the case of a platy particle, or 1 to 10 um in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle, and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
In a further preferred embodiment of the inventive cleansing composition, the particulate optical modifier is composed predominately of platy particles further defined by having an average plate diameter of 10 pm to 200 um and a refractive index of at least 1.8 (preferably having an average plate diameter of about 10 um to 100 ~Zm and a refractive index of at least about 2); and more preferably wherein the particulate optical modifier contains a surface modification selected from amino acids, proteins, fatty acids, lipids, phospholipids (lecithin), anionic and/or cationic oligomers/polymers or blends or derivatives thereof to enhance the deposition of the optical modifier on to the skin.
Preferably the inventive composition contains a cationic polymer having a charge density of at least 0.7 Meq/g (more preferably at least about 0.8, 0.9 or 1.0 Meq/g); still more preferably wherein the cationic polymer is selected from Merquat~ 100 or 2200, Jaguars C17 or C13S, Salcare~ Supre 7, SC10, or SC30; Gafquat ~ HS100 or 755, and Luviquat~
FC370, FC550, HM552 or FC905; or blends thereof.
Advantageously the inventive composition contains an anionic surfactant and optionally an amphoteric surfactant, preferably wherein the anionic surfactant is selected from a C8-C16 alkyl sulfate and/or alkyl ether sulfates, fatty acid soaps, taurates, sulfosuccinates, glycinates, sarcosinates or blends thereof and the amphoteric surfactant is selected from amphoacetates, betaines and amidoalkyl betaines or derivatives or blends thereof.
Advantageously the ratio of anionic surfactant to a surfactant that has a positive charge at a pH of 6.5 or below (preferably where the surfactant has a positive charge at a pH of about 5.5 or below) is in the range of 15:1 to 1:2; in the case of the isotropic composition and is in the range of about 6:1 to about 1:2 in the case of the liquid crystalline structured composition. Preferably wherein the surfactant with the positive charge is an amphoteric surfactant; and more preferably wherein the amphoteric surfactant is selected from betaine, alkylamidopropyl betaine, sulphobetaine, amphoacetate or blends thereof.
In a further preferred embodiment, the solid particulate optical modifier has an average diameter of at least 30 microns (preferably at least about 40, 50, 60, 70, 80, 90, 100, 120, 140, or 150 microns). Preferably the solid particulate optical modifier is present in a minimum concentration of at least 0.2 o by wt. (preferably at least about 0.25, 0.3, 0.4, 0.5, 0.7, 0.~, or 1 o by wt.).
Advantageously the thickening agent for the isotropic composition is selected from polyacrylates; silica; natural and synthetic waxes; aluminum silicate; lanolin derivatives;
C8 to C20 fatty alcohols polyethylene copolymers;
polyammonium carboxylates: sucrose esters; hydrophobic clays; petrolatum; hydrotalcites; cellulose derivatives, polysaccharide derivatives, or derivatives and mixtures thereof. Preferably the isotropic composition is structured with a structurant selected from swelling clays; cross-linked polyacrylates; acrylate homopolymers and copolymers;
polyvinylpyrrolidone homopolymers and copolymers;
polyethylene imines: inorganic salts; sucrose esters, gellants or blends and derivatives thereof.
Advantageously the inventive isotropic structured composition further comprises an emollient having a weight average emollient particle size in the range of 1 to 500 microns; preferably wherein the composition contains less than 10 o by wt. of hydrophobic emollient(s).
More preferably, the isotropic composition has less than 50 o by wt. (preferably less than about 40, 30, 20, 10, or 5 0 by wt.) of the solid particulate optical modifier suspended in an oil. Preferably the isotropic composition contains less than about 10 % by wt. (preferably less than 5, 2, 1, 0.5, 0.1 or 0.05 o by wt.) of hydrophobic emollients) (as defined below) .
In a further preferred embodiment the composition contains at least 7 wt o; preferably 10 to 25 wt o of the surfactant, and preferably the particulate optical modifier is selected from organic pigments, inorganic pigments, polymers, titanium oxide, zinc oxide, colored iron oxide, chromium oxide/hydroxide/hydrate, alumina, silica, zirconia, barium sulfate, silicates, polyethylene, polypropylene, nylon, ultramarine, alkaline earth carbonates, talc, sericite, mica, synthetic mica, polymers, platy substrate coated with organic and inorganic materials, bismuth oxychloride, barium sulfate, or blends and physical aggregates thereof; more preferably wherein the particulate optical modifier pons esses color generated through fluorescence, adsorption, iridescence or a combination thereof. Preferably the inventive composition comprises greater than 30 % by weight water .
In a further aspect of the invention is provided a method of depositing a solid particulate optical modifier onto the skin from a liquid cleansing composition according to any of the preceeding claims, or a blend thereof, comprising the steps of (a) 1 o to 35 wt. o of surfactants) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereof;
(b) 0.1 o to 10 0 of a cationic polymer;
(c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 o change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol described below;
(d) applying said cleansing composition to the skin or hair; and (e) rinsing off said cleansing composition.
Surfactants are an essential component of the inventive cleansing composition. They are compounds that have hydrophobic and hydrophilic portions that act to reduce the surface tension of the aqueous solutions they are dissolved in. Useful surfactants can include anionic, nonionic, amphoteric, and cationic surfactants,, and blends thereof.
The cleansing composition of the present invention may contain one or more anionic detergents. Anionic surfactants are preferably used at levels as low as 3 or 5 or 7 o by wt., and at levels as high as 12 or 15 o by wt.
The anionic detergent active which may be used may be aliphatic sulfonates, such as a primary alkane (e.g., Cg-C~~) sulf onate, primary alkane (e.g., Cg-C2~) disulfonate, Cg-C~~
alkene sulfonate, Cg-C22 hydroxyalkane sulfonate or alkyl glyceryl ether sulfonate (AGS); or aromatic sulfonates such as alkyl benzene sulfonate.
The anionic may also be an alkyl sulfate (e. g., C12-C1g alkyl sulfate) or an alkyl ether sulfate (including alkyl glyceryl ether sulfates). Among the alkyl ether sulfates are those having the formula:
RO(CH2CH20)nS03M
wherein R is an alkyl or alkenyl having 8 to 18 carbons, preferably 12 to 18 carbons, n has an average value of greater than 1.0, preferably greater than 3; and M is a solubilizing cat s on such as sodium, potassium, ammonium or substituted ammonium. Ammonium and sodium lauryl ether sulfates are preferred.
The anionic may also be alkyl sulfosuccinates (including mono- and dialkyl, e.g., C6-C~2 sulfosuccinates); alkyl and acyl taurates, a 1 kyl and acyl sarcosinates, sulfoacetates, Cg-C2~ alkyl phosphates and phosphates, alkyl phosphate esters and alkoxyl alkyl phosphate esters, acyl lactates, Cg-C22 monoalkyl succin ates and maleates, sulphoacetates, alkyl glucosides and a cyl isethionates, and the like.
Sulfosuccinates rnay be monoalkyl sulfosuccinates having the formula:
R 40~CCH~CH(S03M)C02M; and amide-MEA sulfosuccinates of the formula;
R~CONHCH2CH202CCH~CH(S03M)CO~M
wherein R4 range s from Cg-C22 alkyl and M is a solubilizing cation.
Sarcosinates are generally indicated by the formula:
R~CON(CH3)CH2CO~M, wherein R1 ranges from Cg-C2p alkyl and M is a solubilizing canon.
Taurates are generally identified by formula:
R2CONR3CH2CH~S03M
wherein R~ ranges from Cg-C2p alkyl, R3 ranges from C1-C4 alkyl and M is a solubilizing ration.
The inventive cleansing composition may contain Cg-Clg aryl isethionates. These esters are prepared by reaction between alkali metal isethionate with mixed aliphatic fatty acids having from 6 to 18 carbon atoms and an iodine value of less than 20. At least 75 0 of the mixed fatty acids have from 12 to 18 carbon atoms and up to 25 o have from 6 to 10 carbon atoms.
The aryl isethionate may be an alkoxylated isethionate such as is described in Ilardi et al., U.S. Patent No. 5,393,466, titled "Fatty Acid Esters of Polyalkoxylated isethonic acid°', issued February 28, 1995; hereby incorporated by reference.
This compound has the general formula:
I I
R C-0-CH-CH2-(0CH-CH2)m-S03M
wherein R is an alkyl group having 8 to 18 carbons, m is an integer from 1 to 4, X and Y are hydrogen or an alkyl group having 1 to 4 carbons and M+ is a monovalent cation such as, for example, sodium, potassium or ammonium.
One or more amphoteric surfactants may be used in this invention. Amphoteric surfactants are preferably used at levels as low as 0.5 or 0.8 0, and at levels as high as 4 or 5 o by wt. for isotropic compostions or levels as low as 1 or
2 o by wt. and at levels as high as 6 or 8 o by wt. for ordered liquid crystalline compositions. Such surfactants include at least one acid group. This may be a carboxylic or a sulphonic acid group. They include quaternary nitrogen and therefore are quaternary ami do acids. They should generally include an alkyl or alkenyl group of 7 to 18 carbon atoms.
They will usually comply with an overall structural formula:
I
R1- [-C-NH ( CH2 ) n-] m-N+-X-f I
where R1 is alkyl or alkenyl of 7 to 18 carbon atoms; R~ and R3 are each independently a1 kyl, hydroxyalkyl or carboxyalkyl of 1 to 3 carbon atoms; n is 2 to 4; m is 0 to 1; X is alkylene of 1 to 3 carbon atoms opt Tonally substituted with hydroxyl, and Y is -C02- or -S03-Suitable amphoteric surfactants within the above general formula include simple betaines of formula:
I
R1-N+-CH2C0~-I
and amido betaines of formula:
I
R1 - CONH(CH~)n-N+-CH2C02 where n is 3 or 3.
In both formulae R1, R~ and R3 are as defined previously. R1 may in particular be a mixture of C12 and CIg alkyl groups derived from ooconut oil so that at least half, preferably at least three quarters of the groups R1 have 10 to 14 carbon atoms. R~ and R3 are preferably methyl.
A further possibility is that the amphoteric detergent is a sulphobetaine of formula:
R1-N+-(CH2)3503_ ~ R3 or Rl - C01~IH ( CH2 ) m-N+- ( CHI ) 3 S03 _ where m is 2 or 3, or variants of these in which -(CH~)3 S03 is replaced by OH
-CH2CHCH~S03 In these formulae R1, R~ and R3 are as discussed previously.
Amphoacetates and diamphoacetates are also intended to be covered in possible zwitterionic and/or amphoteric compounds which may be used such as e.g., sodium 1 auroamphoacetate, sodium cocoamphoacetate, and blends thereof, and the like.
One or more nonionic surfactants may als o be used in the cleansing composition of the present invention. Nonionic surfactants are preferably used at levels as low as 0.5 or 0.8 and at levels as high as 1.5 or 2 o by wt. for isotropic compositions or at levels as low as 1 or 2 o by wt. and at levels as high as 5 or 6 o by wt. for ordered 1_iquid crystalline compositions.
The nonionics which may be used include in part icular the reaction products of compounds having a hydrophobic group and a reactive hydrogen atom, for example aliphatic alcohols, acids, am3 des or alkylphenols with alkylene oxides, especially ethylene oxide either alone or with propylene oxide. Specific nonionic detergent compounds a re alkyl (C6-C22) phenols ethylene oxide condensates, th a condensation products of aliphatic (Cg-Clg) primary or secondary linear or branched a lcohols with ethylene oxide, and products made by condensat i on of ethylene oxide with the reaction products of propylene oxide and ethylenediamine. Other so- called nonionic detergent compounds include long chain tertiary amine oxides, long chain tertiary phosphine oxides and dialkyl stalphoxide, and the like.
The nonion is may also be a sugar amide, such as a polysaccharide amide. Specifically, the surfactant may be one of the lactobionamides described in U.S. Pa tent No.
5,389,279 to Au et al. titled "Compositions Comprising Nonionic Glycolipid Surfactants" issued Februar y 14, 1995;
which is hereby incorporated by reference, or i t may be one of the sugar amides described in Patent No. 5,009,814 to Relkenberg, titled "Use of N-Poly Hydroxyalkyl Fatty Acid Amides as Thickening Agents for Ziquid Aqueous Surfactant Systems" issued April 23, 1991; hereby incorporated into the subject application by reference.
Suitable thickening agents can be added as a structur ant when the composition is isotropic. Suitable thickening agents include polacrylates; fumed silica natural and synthetic waxes, alkyl silicone waxes such as behenyl silicone wax_; aluminium silicate; lanolin derivatives such as lanesterol; C8 to C20 fatty alcohols;
polyethylenecopolymers; polyammonium stearate; sucros a esters; hydrophobic clays; petrolatum; hydrotalcites; and mixtures thereof, and the like.
Hydrotalcites are materials of general formula:
[MmNn(~H)..~~m+n) ~.n+ X.m n/m Y H2~
g. g. , N is a trivalent where M is a divalent metal ion e. M ~+-metal ion e.g. A1.3+; X is an exchangeable anion e.g. C0.3' , N0.3. , stearate, cinnimate; m is the number of divalent metal ions; and n is the number of trivalent metal ions.
Particularly preferred thickening agents include sill ca, alkyl silicone waxes, paraffin wax, C8 to C20 fatty alcohols, petroleum jelly and polyethylene copolymers, blends thereof and the like.
While some materials can function as both an emollient and a thickener, therefor it will be appreciated that the emollient and thickening function cannot be provided lay the same component. However, it will be understood that where the composition comprises two or more emollients one of said emollients could also function as a thickening agent.
Preferably the amount of thickening agent may be as low as 1 o by wt. and may be up to 5, 10, 15, 20 or 25 o by weight_ Although the isotropi c compositions of the invention may h a self-structuring, pre ferably they will also comprise a structurant, i.e. a material added to increase the viscosity at zero shear. Suitable materials include swelling clays, for example laponite~ fatty acids and derivatives hereof and, in particular fatty acid monoglyceride polyglycol ethers; cross-linked polyacrylates such as Carbopol (TM) (polymers available from Goodrich); acrylates and copolymers thereof e.g. Aqua SF-1 available from Noveon (Cleveland, Ohio), polyvinylpyrr~ lidone and copolymers thereof;
polyethylene imines; salts such as sodium chloride and ammonium sulphate; sucrose esters; gellants; natural gums including alginates, guar, xanthan and polysaccharide derivatives including carboxy methyl cellulose and hydroxypropyl guar; propylene glycols and propylene glycol oleates; glycerol tat lowates; and mixtures thereof, mixtures thereof, and the like.
Of the clays, particularly preferred are synthetic hectori to (laponite) clay used in conjunction with an electrolyte sa It capable of causing t1 a clay to thicken. Suitable electrolytes include alkali and alkaline earth salts such as halides, ammonium salts and sulphates, blends thereof and the like.
Further examples of ~ tructurants and thickeners are given in the International Cosmetic Ingredient Dictionary, Fifth Edition, 1993, published by CTFA (The Cosmetic, Toiletry &
Fragrance Association), incorporated herein by reference.
A necessary comp onent in compositions according to the invention is a cationic skin feel conditioning agent or polymer, such as for example cationic celluloses. Cationic polymers are pre ferably used at levels as low as 0.2 or 0.3, and at levels as high as 1 or 1.5 o by wt. in the case of an isotropic composition, or at levels as low as 0.2 or 0.3 0 and at levels as high as 0.8 or 1 o by wt. in the case of an ordered liquid crystalline composition.
Cationic cellulose is available from Amerchol Corp. (Edison, NJ, USA) in thei r Polymer JR (trade mark) and ZR (trade mark) series of polymers, as salts of hydroxyethyl cellulose reacted with trimethyl ammonium substituted epoxide, referred to in t he industry (CTFA) as Polyquaternium 10.
Another type of cationic cellulose includes the polymeric quaternary ammorzium salts of hydroxyethyl cellulose reacted with lauryl dime thyl ammonium-substituted epoxide, referred to in the industry (CTFA) as Polyquaternium 24. These materials are azrailable from Amerchol Corp. (Edison, NJ, USA) under the t radename Polymer ZM-200.
A particularly suitable type of cationic polysaccharide polymer that can be used is a cationic guar gum derivative, such as guar hydroxypropyltrimonium chloride (Commercially available from Rhone-Poulenc in their JAGUAR trademark series). Examples are JAGUAR C13S, which has a low degree of substitution of the cationic groups and high viscosity, JAGUAR C15, having a moderate degree of substitution and a low viscosity, JAGUAR C17 (high degra a of substitution, high viscosity), JAGUAR C16, which is a hydroxypropylated cationic guar derivative containing a low level of substituent groups as well as cationi o quaternary ammonium groups, and JAGUAR 162 which is a high transparency, medium viscosity guar having a low degree of= substitution.
Particularly preferred cationic polymers are JAGUAR C13S, JAGUAR C15, JAGUAR C17 and JAGUAR C16 and JAGUAR 0162, especially Jaguar C13S. Other cationic skin feel agents known in the art may be used provided that they are compatible with the inventive formulation.
One or more cationic surfactants may also be used in the cleansing composition. Cationic surfactants may be used at levels as low as 0.1, 0..3, 0.5 or 1 0, and at levels as high as 2, 3, 4 or 5 o by wt.
Examples of cationic detergents are the quaternary ammonium compounds such as alkyldimethylammoni_um halogenides.
Other suitable surfactants which may be used are described in U.S. Patent No. 3,723,325 to Parra n Jr. titled "Detergent Compositions Containing Particle Deposition Enhancing Agents" issued March, 27, 1973; and "Surface Active Agents and Detergents" (Vol. T & II) by Sch~,~rartz, Perry & Berch, both of which are also incorporated into the subject application by reference.
In addition, the inventive cleansing composition of the invention may include 0 to 15 o by wt. optional ingredients as follows: perfumes; sequestering agents, such as tetrasodium ethylenediaminetetraacetate (EDTA)~ EHDP or mixtures in an amount of 0.01 to 1 0, preferab ~ y 0.01 to 0.05 o; and coloring agents, opacifiers and pearlize rs such as zinc stearate, magnesium stearate, TiO~, ELMS (ethylene glycol monostearate) or Zytron 621 (Styrene/Acrylate copolymer) and the like; all of which are useful in enhancing the appearance or cosmetic properties of the product.
The compositions may further comprise antimicr obials such as 2-hydroxy-4,2', 4' trichlorodiphenylether (DP300);
preservatives such as dimethyloldimethylhydant o in (Glydant XZ1000), parabens, sorbic acid etc., and the 1~ ke.
The compositions may also comprise coconut aryl mono- or diethanol amides as suds boosters, and strongly ionizing salts such as sodium chloride and sodium sulfate may also be used to advantage.
Antioxidants such as, for example, butylated h~droxytoluene (BHT) and the like may be used advantageously ~n amounts of 0.01 0 or higher if appropriate.
Moisturizers that also are humectants such as p olyhydric alcohols, e.g. glycerine and propylene glycol, and the like;
and polyols such as the polyethylene glycols listed below and the like may be used.
Polyox WSR-205 PEG 14M, Polyox WSR-N-60K PEG 45M, or Polyox WSR-N-750 PEG 7M.
Hydrophobic and/or hydrophilic emollients (i.e . humectants) mentioned above may be used. Preferably, hydrophilic emollients are used in excess of hydrophobic emollients in the inventive cleansing composition. Most pre.terably one or more hydrophilic emollients are used alone. Hydrophilic emollients are preferably present in a concentration greater than 0.01 o by weight, more preferably greater than 0.5 o by weight. Preferably the inventive composition contains less than 10, 5, 3, 2, 1, 0.7, 0.5, 0.3, 0.2, 0.1, 0.05 or 0.01 0 by wt. of a hydrophobic emollient in the case of an isotropic composition. Hydrophobic emollients are prefezably present in a concentration greater than 3, 5, 7, 9, 10, 15, 20, or 25 o by weight in the case of an ordered liquid czystalline composition.
The term "emollient" is defined as a substance which softens or improves the elasticity, appearance, and yo-~zthfulness of the skin (stratum corneum) by either increasing its water content, adding, or replacing lipids and other skin nutrients, or both; and keeps it soft by retarding the decrease of its water content.
Useful emollients (also considered conditioning compounds according to the invention) include the followsng:
(a) silicone oils and modifications thereo f such as linear and cyclic polydimethylsiloxanes; amino, alkyl, alkylaryl, and aryl silicone o ~ 1s;
(b) fats and oils including natural fats and oils such as jojoba, soybean, sunflower, rice bran avocado, _ 27 _ almond, olive, sesame, persic, castor, coconut, mink oils; cacao fat; beef tallow, lard; harden ed oils obtained by hydrogenating the aforementiorzed oils;
and synthetic mono-, di- and triglycerides such as myristic acid glyceride and 2-ethylhexanoi c acid glyceride;
(c) waxes such as carnauba, spermaceti, beeswa x, lanolin, and derivatives thereof;
(d) hydrophobic and hydrophillic plant extract s;
(e) hydrocarbons such as liquid paraffins, vas eline, microcrystalline wax, ceresin, squalene, p ristan and mineral oil;
(f) higher fatty acids such as lauric, myristi c, palmitic, stearic, behenic, oleic, linolei c, linolenic, lanolic, isostearic, arachidoni c and poly unsaturated fatty acids (PUFA);
(g) higher alcohols such as lauryl, cetyl, ste aryl, oleyl, behenyl, cholesterol and 2-hexydeca nol alcohol;
(h) esters such as cetyl octanoate, myristyl 1 actate, cetyl lactate, isopropyl myristate, myrist y1 myristate, isopropyl palmitate, isopropyl adipate, butyl stearate, decyl oleate, cholesterol isostearate, glycerol monostearate, glycer-of distearate, glycerol tristearate, alkyl lactate, alkyl citrate and alkyl tartrate;
(i) essential oils and extracts thereof such a s mentha, jasmine, camphor, white cedar, bitter orange peel, ryu, turpentine, cinnamon, bergamot, citru s unshiu, calamus, pine, lavender, bay, clove, hiba, eucalyptus, lemon, starflower, thyme, peep ermint, rose, sage, sesame, ginger, basil, juniper, lemon grass, rosemary, rosewood, avocado, grape grapeseed, myrrh, cucumber, watercress, calendula, e? der flower, geranium, linden blossom, amaranth, seawee d, gin ko, ginseng, carrot, guarana, tea tree, jojoba, comfrey, oatmeal, cocoa, neroli, vanilla, green tee, penny royal, aloe vera, menthol, cineole, eugenol, citral, citronelle, borneol, linalool, geraniol, evening primrose, camphor, thymol, spirantol, penene, limonene and terpenoid oils; and (j) mixtures of any of the foregoing components, and the like.
Preferred conditioning agents are selected from glycerin, triglyceride oils, mineral oils, petrolatum, and mixtures thereof. Further preferred emollients are glycerin, triglycerides such as shea butter and sunflower seed oil.
In preferred embodiment, the inventive cleansing composition possesses either isotropic micellar phase, ordere d liquid crystalline phase microstructure (preferably lamell ar microstructure structure), or a combination thereof . The rheological behavior of all surfactant solutions, including liquid cleansing solutions, is strongly dependent on the microstructure, i.e., the shape and concentration ~ f micelles or other self-assembled structures in solution.
When there is sufficient surfactant to form micelle s (concentrations above the critical micelle concentration or CMC), for example, spherical, cylindrical (rod-like or discoidal), spherocylindrical or ellipsoidal micelles may form. As surfactant concentration increases, ordered liquid crystalline phases such as lamellar phase, hexagonal phase, cubic phase or Z3 sponge phase may form. The lamellar phase, for example, consists of alternating surfactant bilayers and water layers. These layers are not generally flat, but fold to form submicron spherical onion like structures called vesicles or liposomes. The hexagonal phase, on the other hand, consists of long cylindrical micelles arranged in a hexagonal lattice. In general, the microstructure of most personal care products consist of either spherical micelles, rod micelles, or a lamellar dispersion.
As noted above, micelles may be spherical or rod-like.
Formulations having spherical micelles tend to have a low viscosity and exhibit Newtonian shear behavior (i.e., the viscosity stays constant as a function of shear rate; thus, if easy pouring of product is desired, the solution is less viscous and, as a consequence, it doesn't suspend as well .
In these systems, the viscosity increases linearly with surfactant concentration.
Rod micellar solutions are more viscous because movement o f the longer micelles is restricted. At a critical shear rate, the micelles align and the solution becomes shear thinning. Addition of salts increases the size of the rod micelles thereof increasing zero shear viscosity (i.e., viscosity when sitting in bottle) which helps suspend particles, but also increases critical shear rate (i.e. the point at which the product becomes shear thinning; higher critical shear rates means product is more difficult to pour ) .
Zamellar dispersions differ from both spherical and rod-like micelles because they can have high zero shear viscosity (because of the close packed arrangement of constituent lamellar droplets), yet these solutions are very shear thinning (e.g. readily dispense on pouring). That is, the solutions can become thinner than rod micellar solutions at moderate shear rates.
In formulating liquid cleansing compositions, therefore, there is the choice of using rod-micellar solutions (whose zero shear viscosity, e.g., suspending ability, is not very good and/or are not very shear thinning); or lamellar dispersions (with higher zero shear viscosity, e.g. better suspending, and yet are very shear thinning). Such lamellar compositions are characterized by high zero shear viscosity (good for suspending and/or structuring) while simultaneously being very shear thinning such that they readily dispense in pouring. Such compositions possess a "heaping", lotion-like appearance which convey signals of enhanced moisturization.
Tnlhen rod-micellar solutions are used, they also often require the use of external structurants to enhance viscosity and to suspend particles (again, because they have lower zero shear viscosity than lamellar phase solutions).
For this, carbomers and clays are often used. At higher shear rates (as in product dispensing, application of product to body, or rubbing with hands), since the rod-micellar solutions are less shear thinning, the viscosity of the solution stays high and the product can be stringy and thick. Lamellar dispersion based products, having higher zero shear viscosity, can more readily suspend emollients and are typically more creamy. In general, lamellar phase compositions are easy to identify by their characteristic focal conic shape and oily streak texture while hexagonal phase exhibits angular fan-like texture. In contrast, micellar phases are optically isotropic.
It should be understood that lamellar phases may be formed in a wide variety of surfactant systems using a wide variety of lamellar phase "inducers" as described, for example, in U.S. Pat. No. 5,952,286 issued to Puvvada, et al., on September, 14, 1999. Generally, the transition from micelle to lamellar phase are functions of effective average area of headgroup of the surfactant, the length of the extended tail, and the volume of tail. Using branched surfactants or surfactants with smaller headgroups or bulky tails are also effective ways of inducing transitions from rod micellar to lamellar.
One way of characterizing isotropic micellar dispersions (hereinafter "isotropic compositions") include cone and plate viscosity measurement as described below. The inventive isotropic composition has a viscosity in the range of 1,000 to 300,000 cps @ 1/sec shear rate at 25°C as measured by a cone and plate technique described below. Preferably the viscosity is in the range of 5,000 to 50,000 cps.
One way of characterizing ordered liquid crystalline dispersions include measuring viscosity at low shear rate (using for example a Stress Rheometer) when additional inducer (e.g., oleic acid or isostearic acid) is used. At higher amounts of inducer, the low shear viscosity will significantly increase.
Another way of measuring ordered liquid crystalline dispersions is using freeze fracture electron microscopy.
Micrographs generally will show ordered liquid crystalline microstructure and close packed organization of the lamellar droplets (generally in size range of 2 microns).
The inventive ordered liquid crystalline-isotropic composition preferably has a low shear viscosity in the range of 40,000 to 300,000 centipoises (cps) measured at 0.5 RPM using T-bar spindle A using the procedure described below. More preferably the viscosity range is 50,000 to 150,000 cps.
An important component of compositions according to the present invention is that of solid particulate optical modifiers, preferably light reflecting platelet shaped or platy particles. These particles will preferably have an average particle size D5p ranging from 25,000 to 150,000 nm.
For plate-like materials the average particle size is a number average value. The platelets are assumed to have a circular shape with the diameter of the circular surface averaged over many particles. The thickness of the plate-like particles is considered to be a separate parameter.
For instance, the platelets can have an average particle size of 35,000 nm and an average thickness of 400 nm. For purposes herein, thickness is considered to range from 100 to 600 nm. Laser light scattering can be utilized for measurement, except that light scattered data has to be mathematically corrected from the spherical to the non-spherical shape. Optical and electron microscopy may be used to determine average particle size. Thickness is normally only determined via optical or electron microscopy.
The refractive index of these particles is preferred to be at least 1.8, generally from 1.9 to 4, more preferably from 2 to 3, optimally between 2.5 and 2.8.
Illustrative but not limiting examples of light reflecting particles are bismuth oxychloride (single crystal platelets) and titanium dioxide and/or iron oxide coated. mica.
Suitable bismuth oxychloride crystals are available from EM
Industries, Inc. under the trademarks Biron~ NLY-L-2X CO and Biron~ Silver CO (wherein the platelets are dispersed in castor oil); Biron~ Liquid Silver (wherein the particles are dispersed in a stearate ester); and Nailsyn~ IGO, Nailsyn~
II C2X and Nailsyn~ II Platinum 25 (wherein the platelets are dispersed in nitrocellulose). Most preferred is a system where bismuth oxychloride is dispersed in a C2 - C40 alkyl ester such as in Biron~ Liquid Silver.
.Among the suitable titanium dioxide coated mica platelets are materials available from EM Industries, Inc. These include TimironO MP-45 (particle size range 49,000 - 57,000 nm), Timiron~ MP- 99 (particle size range 47,000 - 57,000 nm), Tsmiron~ MP-47 (particle size range 28,000 - 38,000 nm), Timiron~ MP-149 (particle size range 65,000 - 82,000 nm), and Timiron~ MP-18 (particle size range 41,000 - 51,000 nm). Most preferred is Timiron~ MP-149. The weight ratio of tit anium dioxide coating to the mica platelet may range from 1:10 to 5:1, preferably from 1:6 to 1:7, by weight.
Advantageously the preferred compositions will generally be substantially free of titanium dioxide outside of that required for coating mica.
Among the suitable iron oxide and titanium dioxide coated mica platelets are materials available from EM Industires, Inc. These include Timiron~ MP-28 (particle size range 27,000 - 37,000 nm), Timiron~ MP-29 (particle size range 47,000 - 55,000 nm), and Timiron~ MP-24 (particle size range 56,000 - 70,000 nm). Most prefered is Timiron~ MP-24.
Among the suitable iron oxide coated mica platelets are materials available from EM Industires, Inc. These include Coloron a~ Bronze Sparkle (particle size range 28,000 -42,000 nm), Colorona~ Glitter Bronze (particle size range 65,000 - 82,000 nm), Colorona~ Copper Sparkle (particle size range 25,000 - 39,000 nm), and Colorona~ Glitter Copper (particle size range 65,000 - 82,000 nm).
Suitable coatings for mica other than titanium dioxide and iron oxide rnay also achieve the appropriate optical properties required for the present invention. These types of coated micas must also meet the refractive index of at least 1.8. Other coatings include silica on the mica platelets.
Advantageou sly, optional active agents other than conditionin g agents such as emollients or moisturizers defined above may be added to the cleansing composition in a safe and effective amount during formulation to treat the skin during the use of the product. These active ingredients may be advantageously selected from antimicrobi al and antifungal actives, vitamins, anti-acne actives; anti-wrinkle, anti-skin atrophy and skin repair actives; sksn barrier repair actives; non- steroidal cosmetic soothing actives; artificial tanning agents and accelerators; skin lightening actives; sunscreen actives;
sebum stimulators; sebum inhibitors; anti-oxidants; protease inhibitors; skin tightening agents; anti-itch ingredients;
hair growth inhibitors; 5-alpha reductase inhibitors;
desquamatin g enzyme enhancers; anti-glycation agents;
topical anesthetics, or mixtures thereof; and the like.
These active agents may be selected from water-soluble active agents, oil soluble active agents, pharmaceutically-acceptable salts and mixtures thereof. Advantageously the agents will be soluble or dispersible in the cleansing composition. The term "active agent" as used herein, means personal care actives which can be used to deliver a benefit to the skin and/or hair and which generally are not used to confer a condition ing benefit, as is conferred by humectants and emollients pre viously described herein. The term "safe and effective amount" as used herein, means an amount of active agent high enough to modify the condition to be treated or to deli ver the desired skin care benefit, but low enough to avoid serious side effects. The term "benefit,"
as used herein, means the therapeutic, prophylactic, and/or chronic benefits associated with treating a particular condition with one or more of the active agents described herein.
What is a safe and effective amount of the active agent ingredient will vary with the specific active agent, the ability of the act ive to penetrate through the skin, the age, health condit zon, and skin condition of the user, and other like factors. Preferably the composition of the present invention comprise from 0.01 o to 50 0, more preferably from 0.05 o to 25 0, even more preferably 0.1 0 to 10 0, and most preferably 0.1 o to 5 0, by weight of the active agent component.
Anti-acne actives can be effective in treating acne vulgaris, a chroni c disorder of the pilosebaceous follicles.
Non-limiting e~amp 1es of useful anti-acne actives include ~5 the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid and 4 methoxysalicylic acid, and resorcinol;
retinoids such as retinoic acid and its derivatives (e. g., cis and trans); sulfur-containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, mixtures thereof and the like.
Anti-microbial and anti-fungal actives can be effective to prevent the proliferation and growth of bacteria and fungi.
Non-limiting examples of anti-microbial and anti-fungal actives include b-lactam drugs, quinolone drugs, ciprofloxacin, norfloxa cin, tetracycline, erythromycin, amikacin, 2,4,4-trichl oro-2~-hydroxy Biphenyl ether,
They will usually comply with an overall structural formula:
I
R1- [-C-NH ( CH2 ) n-] m-N+-X-f I
where R1 is alkyl or alkenyl of 7 to 18 carbon atoms; R~ and R3 are each independently a1 kyl, hydroxyalkyl or carboxyalkyl of 1 to 3 carbon atoms; n is 2 to 4; m is 0 to 1; X is alkylene of 1 to 3 carbon atoms opt Tonally substituted with hydroxyl, and Y is -C02- or -S03-Suitable amphoteric surfactants within the above general formula include simple betaines of formula:
I
R1-N+-CH2C0~-I
and amido betaines of formula:
I
R1 - CONH(CH~)n-N+-CH2C02 where n is 3 or 3.
In both formulae R1, R~ and R3 are as defined previously. R1 may in particular be a mixture of C12 and CIg alkyl groups derived from ooconut oil so that at least half, preferably at least three quarters of the groups R1 have 10 to 14 carbon atoms. R~ and R3 are preferably methyl.
A further possibility is that the amphoteric detergent is a sulphobetaine of formula:
R1-N+-(CH2)3503_ ~ R3 or Rl - C01~IH ( CH2 ) m-N+- ( CHI ) 3 S03 _ where m is 2 or 3, or variants of these in which -(CH~)3 S03 is replaced by OH
-CH2CHCH~S03 In these formulae R1, R~ and R3 are as discussed previously.
Amphoacetates and diamphoacetates are also intended to be covered in possible zwitterionic and/or amphoteric compounds which may be used such as e.g., sodium 1 auroamphoacetate, sodium cocoamphoacetate, and blends thereof, and the like.
One or more nonionic surfactants may als o be used in the cleansing composition of the present invention. Nonionic surfactants are preferably used at levels as low as 0.5 or 0.8 and at levels as high as 1.5 or 2 o by wt. for isotropic compositions or at levels as low as 1 or 2 o by wt. and at levels as high as 5 or 6 o by wt. for ordered 1_iquid crystalline compositions.
The nonionics which may be used include in part icular the reaction products of compounds having a hydrophobic group and a reactive hydrogen atom, for example aliphatic alcohols, acids, am3 des or alkylphenols with alkylene oxides, especially ethylene oxide either alone or with propylene oxide. Specific nonionic detergent compounds a re alkyl (C6-C22) phenols ethylene oxide condensates, th a condensation products of aliphatic (Cg-Clg) primary or secondary linear or branched a lcohols with ethylene oxide, and products made by condensat i on of ethylene oxide with the reaction products of propylene oxide and ethylenediamine. Other so- called nonionic detergent compounds include long chain tertiary amine oxides, long chain tertiary phosphine oxides and dialkyl stalphoxide, and the like.
The nonion is may also be a sugar amide, such as a polysaccharide amide. Specifically, the surfactant may be one of the lactobionamides described in U.S. Pa tent No.
5,389,279 to Au et al. titled "Compositions Comprising Nonionic Glycolipid Surfactants" issued Februar y 14, 1995;
which is hereby incorporated by reference, or i t may be one of the sugar amides described in Patent No. 5,009,814 to Relkenberg, titled "Use of N-Poly Hydroxyalkyl Fatty Acid Amides as Thickening Agents for Ziquid Aqueous Surfactant Systems" issued April 23, 1991; hereby incorporated into the subject application by reference.
Suitable thickening agents can be added as a structur ant when the composition is isotropic. Suitable thickening agents include polacrylates; fumed silica natural and synthetic waxes, alkyl silicone waxes such as behenyl silicone wax_; aluminium silicate; lanolin derivatives such as lanesterol; C8 to C20 fatty alcohols;
polyethylenecopolymers; polyammonium stearate; sucros a esters; hydrophobic clays; petrolatum; hydrotalcites; and mixtures thereof, and the like.
Hydrotalcites are materials of general formula:
[MmNn(~H)..~~m+n) ~.n+ X.m n/m Y H2~
g. g. , N is a trivalent where M is a divalent metal ion e. M ~+-metal ion e.g. A1.3+; X is an exchangeable anion e.g. C0.3' , N0.3. , stearate, cinnimate; m is the number of divalent metal ions; and n is the number of trivalent metal ions.
Particularly preferred thickening agents include sill ca, alkyl silicone waxes, paraffin wax, C8 to C20 fatty alcohols, petroleum jelly and polyethylene copolymers, blends thereof and the like.
While some materials can function as both an emollient and a thickener, therefor it will be appreciated that the emollient and thickening function cannot be provided lay the same component. However, it will be understood that where the composition comprises two or more emollients one of said emollients could also function as a thickening agent.
Preferably the amount of thickening agent may be as low as 1 o by wt. and may be up to 5, 10, 15, 20 or 25 o by weight_ Although the isotropi c compositions of the invention may h a self-structuring, pre ferably they will also comprise a structurant, i.e. a material added to increase the viscosity at zero shear. Suitable materials include swelling clays, for example laponite~ fatty acids and derivatives hereof and, in particular fatty acid monoglyceride polyglycol ethers; cross-linked polyacrylates such as Carbopol (TM) (polymers available from Goodrich); acrylates and copolymers thereof e.g. Aqua SF-1 available from Noveon (Cleveland, Ohio), polyvinylpyrr~ lidone and copolymers thereof;
polyethylene imines; salts such as sodium chloride and ammonium sulphate; sucrose esters; gellants; natural gums including alginates, guar, xanthan and polysaccharide derivatives including carboxy methyl cellulose and hydroxypropyl guar; propylene glycols and propylene glycol oleates; glycerol tat lowates; and mixtures thereof, mixtures thereof, and the like.
Of the clays, particularly preferred are synthetic hectori to (laponite) clay used in conjunction with an electrolyte sa It capable of causing t1 a clay to thicken. Suitable electrolytes include alkali and alkaline earth salts such as halides, ammonium salts and sulphates, blends thereof and the like.
Further examples of ~ tructurants and thickeners are given in the International Cosmetic Ingredient Dictionary, Fifth Edition, 1993, published by CTFA (The Cosmetic, Toiletry &
Fragrance Association), incorporated herein by reference.
A necessary comp onent in compositions according to the invention is a cationic skin feel conditioning agent or polymer, such as for example cationic celluloses. Cationic polymers are pre ferably used at levels as low as 0.2 or 0.3, and at levels as high as 1 or 1.5 o by wt. in the case of an isotropic composition, or at levels as low as 0.2 or 0.3 0 and at levels as high as 0.8 or 1 o by wt. in the case of an ordered liquid crystalline composition.
Cationic cellulose is available from Amerchol Corp. (Edison, NJ, USA) in thei r Polymer JR (trade mark) and ZR (trade mark) series of polymers, as salts of hydroxyethyl cellulose reacted with trimethyl ammonium substituted epoxide, referred to in t he industry (CTFA) as Polyquaternium 10.
Another type of cationic cellulose includes the polymeric quaternary ammorzium salts of hydroxyethyl cellulose reacted with lauryl dime thyl ammonium-substituted epoxide, referred to in the industry (CTFA) as Polyquaternium 24. These materials are azrailable from Amerchol Corp. (Edison, NJ, USA) under the t radename Polymer ZM-200.
A particularly suitable type of cationic polysaccharide polymer that can be used is a cationic guar gum derivative, such as guar hydroxypropyltrimonium chloride (Commercially available from Rhone-Poulenc in their JAGUAR trademark series). Examples are JAGUAR C13S, which has a low degree of substitution of the cationic groups and high viscosity, JAGUAR C15, having a moderate degree of substitution and a low viscosity, JAGUAR C17 (high degra a of substitution, high viscosity), JAGUAR C16, which is a hydroxypropylated cationic guar derivative containing a low level of substituent groups as well as cationi o quaternary ammonium groups, and JAGUAR 162 which is a high transparency, medium viscosity guar having a low degree of= substitution.
Particularly preferred cationic polymers are JAGUAR C13S, JAGUAR C15, JAGUAR C17 and JAGUAR C16 and JAGUAR 0162, especially Jaguar C13S. Other cationic skin feel agents known in the art may be used provided that they are compatible with the inventive formulation.
One or more cationic surfactants may also be used in the cleansing composition. Cationic surfactants may be used at levels as low as 0.1, 0..3, 0.5 or 1 0, and at levels as high as 2, 3, 4 or 5 o by wt.
Examples of cationic detergents are the quaternary ammonium compounds such as alkyldimethylammoni_um halogenides.
Other suitable surfactants which may be used are described in U.S. Patent No. 3,723,325 to Parra n Jr. titled "Detergent Compositions Containing Particle Deposition Enhancing Agents" issued March, 27, 1973; and "Surface Active Agents and Detergents" (Vol. T & II) by Sch~,~rartz, Perry & Berch, both of which are also incorporated into the subject application by reference.
In addition, the inventive cleansing composition of the invention may include 0 to 15 o by wt. optional ingredients as follows: perfumes; sequestering agents, such as tetrasodium ethylenediaminetetraacetate (EDTA)~ EHDP or mixtures in an amount of 0.01 to 1 0, preferab ~ y 0.01 to 0.05 o; and coloring agents, opacifiers and pearlize rs such as zinc stearate, magnesium stearate, TiO~, ELMS (ethylene glycol monostearate) or Zytron 621 (Styrene/Acrylate copolymer) and the like; all of which are useful in enhancing the appearance or cosmetic properties of the product.
The compositions may further comprise antimicr obials such as 2-hydroxy-4,2', 4' trichlorodiphenylether (DP300);
preservatives such as dimethyloldimethylhydant o in (Glydant XZ1000), parabens, sorbic acid etc., and the 1~ ke.
The compositions may also comprise coconut aryl mono- or diethanol amides as suds boosters, and strongly ionizing salts such as sodium chloride and sodium sulfate may also be used to advantage.
Antioxidants such as, for example, butylated h~droxytoluene (BHT) and the like may be used advantageously ~n amounts of 0.01 0 or higher if appropriate.
Moisturizers that also are humectants such as p olyhydric alcohols, e.g. glycerine and propylene glycol, and the like;
and polyols such as the polyethylene glycols listed below and the like may be used.
Polyox WSR-205 PEG 14M, Polyox WSR-N-60K PEG 45M, or Polyox WSR-N-750 PEG 7M.
Hydrophobic and/or hydrophilic emollients (i.e . humectants) mentioned above may be used. Preferably, hydrophilic emollients are used in excess of hydrophobic emollients in the inventive cleansing composition. Most pre.terably one or more hydrophilic emollients are used alone. Hydrophilic emollients are preferably present in a concentration greater than 0.01 o by weight, more preferably greater than 0.5 o by weight. Preferably the inventive composition contains less than 10, 5, 3, 2, 1, 0.7, 0.5, 0.3, 0.2, 0.1, 0.05 or 0.01 0 by wt. of a hydrophobic emollient in the case of an isotropic composition. Hydrophobic emollients are prefezably present in a concentration greater than 3, 5, 7, 9, 10, 15, 20, or 25 o by weight in the case of an ordered liquid czystalline composition.
The term "emollient" is defined as a substance which softens or improves the elasticity, appearance, and yo-~zthfulness of the skin (stratum corneum) by either increasing its water content, adding, or replacing lipids and other skin nutrients, or both; and keeps it soft by retarding the decrease of its water content.
Useful emollients (also considered conditioning compounds according to the invention) include the followsng:
(a) silicone oils and modifications thereo f such as linear and cyclic polydimethylsiloxanes; amino, alkyl, alkylaryl, and aryl silicone o ~ 1s;
(b) fats and oils including natural fats and oils such as jojoba, soybean, sunflower, rice bran avocado, _ 27 _ almond, olive, sesame, persic, castor, coconut, mink oils; cacao fat; beef tallow, lard; harden ed oils obtained by hydrogenating the aforementiorzed oils;
and synthetic mono-, di- and triglycerides such as myristic acid glyceride and 2-ethylhexanoi c acid glyceride;
(c) waxes such as carnauba, spermaceti, beeswa x, lanolin, and derivatives thereof;
(d) hydrophobic and hydrophillic plant extract s;
(e) hydrocarbons such as liquid paraffins, vas eline, microcrystalline wax, ceresin, squalene, p ristan and mineral oil;
(f) higher fatty acids such as lauric, myristi c, palmitic, stearic, behenic, oleic, linolei c, linolenic, lanolic, isostearic, arachidoni c and poly unsaturated fatty acids (PUFA);
(g) higher alcohols such as lauryl, cetyl, ste aryl, oleyl, behenyl, cholesterol and 2-hexydeca nol alcohol;
(h) esters such as cetyl octanoate, myristyl 1 actate, cetyl lactate, isopropyl myristate, myrist y1 myristate, isopropyl palmitate, isopropyl adipate, butyl stearate, decyl oleate, cholesterol isostearate, glycerol monostearate, glycer-of distearate, glycerol tristearate, alkyl lactate, alkyl citrate and alkyl tartrate;
(i) essential oils and extracts thereof such a s mentha, jasmine, camphor, white cedar, bitter orange peel, ryu, turpentine, cinnamon, bergamot, citru s unshiu, calamus, pine, lavender, bay, clove, hiba, eucalyptus, lemon, starflower, thyme, peep ermint, rose, sage, sesame, ginger, basil, juniper, lemon grass, rosemary, rosewood, avocado, grape grapeseed, myrrh, cucumber, watercress, calendula, e? der flower, geranium, linden blossom, amaranth, seawee d, gin ko, ginseng, carrot, guarana, tea tree, jojoba, comfrey, oatmeal, cocoa, neroli, vanilla, green tee, penny royal, aloe vera, menthol, cineole, eugenol, citral, citronelle, borneol, linalool, geraniol, evening primrose, camphor, thymol, spirantol, penene, limonene and terpenoid oils; and (j) mixtures of any of the foregoing components, and the like.
Preferred conditioning agents are selected from glycerin, triglyceride oils, mineral oils, petrolatum, and mixtures thereof. Further preferred emollients are glycerin, triglycerides such as shea butter and sunflower seed oil.
In preferred embodiment, the inventive cleansing composition possesses either isotropic micellar phase, ordere d liquid crystalline phase microstructure (preferably lamell ar microstructure structure), or a combination thereof . The rheological behavior of all surfactant solutions, including liquid cleansing solutions, is strongly dependent on the microstructure, i.e., the shape and concentration ~ f micelles or other self-assembled structures in solution.
When there is sufficient surfactant to form micelle s (concentrations above the critical micelle concentration or CMC), for example, spherical, cylindrical (rod-like or discoidal), spherocylindrical or ellipsoidal micelles may form. As surfactant concentration increases, ordered liquid crystalline phases such as lamellar phase, hexagonal phase, cubic phase or Z3 sponge phase may form. The lamellar phase, for example, consists of alternating surfactant bilayers and water layers. These layers are not generally flat, but fold to form submicron spherical onion like structures called vesicles or liposomes. The hexagonal phase, on the other hand, consists of long cylindrical micelles arranged in a hexagonal lattice. In general, the microstructure of most personal care products consist of either spherical micelles, rod micelles, or a lamellar dispersion.
As noted above, micelles may be spherical or rod-like.
Formulations having spherical micelles tend to have a low viscosity and exhibit Newtonian shear behavior (i.e., the viscosity stays constant as a function of shear rate; thus, if easy pouring of product is desired, the solution is less viscous and, as a consequence, it doesn't suspend as well .
In these systems, the viscosity increases linearly with surfactant concentration.
Rod micellar solutions are more viscous because movement o f the longer micelles is restricted. At a critical shear rate, the micelles align and the solution becomes shear thinning. Addition of salts increases the size of the rod micelles thereof increasing zero shear viscosity (i.e., viscosity when sitting in bottle) which helps suspend particles, but also increases critical shear rate (i.e. the point at which the product becomes shear thinning; higher critical shear rates means product is more difficult to pour ) .
Zamellar dispersions differ from both spherical and rod-like micelles because they can have high zero shear viscosity (because of the close packed arrangement of constituent lamellar droplets), yet these solutions are very shear thinning (e.g. readily dispense on pouring). That is, the solutions can become thinner than rod micellar solutions at moderate shear rates.
In formulating liquid cleansing compositions, therefore, there is the choice of using rod-micellar solutions (whose zero shear viscosity, e.g., suspending ability, is not very good and/or are not very shear thinning); or lamellar dispersions (with higher zero shear viscosity, e.g. better suspending, and yet are very shear thinning). Such lamellar compositions are characterized by high zero shear viscosity (good for suspending and/or structuring) while simultaneously being very shear thinning such that they readily dispense in pouring. Such compositions possess a "heaping", lotion-like appearance which convey signals of enhanced moisturization.
Tnlhen rod-micellar solutions are used, they also often require the use of external structurants to enhance viscosity and to suspend particles (again, because they have lower zero shear viscosity than lamellar phase solutions).
For this, carbomers and clays are often used. At higher shear rates (as in product dispensing, application of product to body, or rubbing with hands), since the rod-micellar solutions are less shear thinning, the viscosity of the solution stays high and the product can be stringy and thick. Lamellar dispersion based products, having higher zero shear viscosity, can more readily suspend emollients and are typically more creamy. In general, lamellar phase compositions are easy to identify by their characteristic focal conic shape and oily streak texture while hexagonal phase exhibits angular fan-like texture. In contrast, micellar phases are optically isotropic.
It should be understood that lamellar phases may be formed in a wide variety of surfactant systems using a wide variety of lamellar phase "inducers" as described, for example, in U.S. Pat. No. 5,952,286 issued to Puvvada, et al., on September, 14, 1999. Generally, the transition from micelle to lamellar phase are functions of effective average area of headgroup of the surfactant, the length of the extended tail, and the volume of tail. Using branched surfactants or surfactants with smaller headgroups or bulky tails are also effective ways of inducing transitions from rod micellar to lamellar.
One way of characterizing isotropic micellar dispersions (hereinafter "isotropic compositions") include cone and plate viscosity measurement as described below. The inventive isotropic composition has a viscosity in the range of 1,000 to 300,000 cps @ 1/sec shear rate at 25°C as measured by a cone and plate technique described below. Preferably the viscosity is in the range of 5,000 to 50,000 cps.
One way of characterizing ordered liquid crystalline dispersions include measuring viscosity at low shear rate (using for example a Stress Rheometer) when additional inducer (e.g., oleic acid or isostearic acid) is used. At higher amounts of inducer, the low shear viscosity will significantly increase.
Another way of measuring ordered liquid crystalline dispersions is using freeze fracture electron microscopy.
Micrographs generally will show ordered liquid crystalline microstructure and close packed organization of the lamellar droplets (generally in size range of 2 microns).
The inventive ordered liquid crystalline-isotropic composition preferably has a low shear viscosity in the range of 40,000 to 300,000 centipoises (cps) measured at 0.5 RPM using T-bar spindle A using the procedure described below. More preferably the viscosity range is 50,000 to 150,000 cps.
An important component of compositions according to the present invention is that of solid particulate optical modifiers, preferably light reflecting platelet shaped or platy particles. These particles will preferably have an average particle size D5p ranging from 25,000 to 150,000 nm.
For plate-like materials the average particle size is a number average value. The platelets are assumed to have a circular shape with the diameter of the circular surface averaged over many particles. The thickness of the plate-like particles is considered to be a separate parameter.
For instance, the platelets can have an average particle size of 35,000 nm and an average thickness of 400 nm. For purposes herein, thickness is considered to range from 100 to 600 nm. Laser light scattering can be utilized for measurement, except that light scattered data has to be mathematically corrected from the spherical to the non-spherical shape. Optical and electron microscopy may be used to determine average particle size. Thickness is normally only determined via optical or electron microscopy.
The refractive index of these particles is preferred to be at least 1.8, generally from 1.9 to 4, more preferably from 2 to 3, optimally between 2.5 and 2.8.
Illustrative but not limiting examples of light reflecting particles are bismuth oxychloride (single crystal platelets) and titanium dioxide and/or iron oxide coated. mica.
Suitable bismuth oxychloride crystals are available from EM
Industries, Inc. under the trademarks Biron~ NLY-L-2X CO and Biron~ Silver CO (wherein the platelets are dispersed in castor oil); Biron~ Liquid Silver (wherein the particles are dispersed in a stearate ester); and Nailsyn~ IGO, Nailsyn~
II C2X and Nailsyn~ II Platinum 25 (wherein the platelets are dispersed in nitrocellulose). Most preferred is a system where bismuth oxychloride is dispersed in a C2 - C40 alkyl ester such as in Biron~ Liquid Silver.
.Among the suitable titanium dioxide coated mica platelets are materials available from EM Industries, Inc. These include TimironO MP-45 (particle size range 49,000 - 57,000 nm), Timiron~ MP- 99 (particle size range 47,000 - 57,000 nm), Tsmiron~ MP-47 (particle size range 28,000 - 38,000 nm), Timiron~ MP-149 (particle size range 65,000 - 82,000 nm), and Timiron~ MP-18 (particle size range 41,000 - 51,000 nm). Most preferred is Timiron~ MP-149. The weight ratio of tit anium dioxide coating to the mica platelet may range from 1:10 to 5:1, preferably from 1:6 to 1:7, by weight.
Advantageously the preferred compositions will generally be substantially free of titanium dioxide outside of that required for coating mica.
Among the suitable iron oxide and titanium dioxide coated mica platelets are materials available from EM Industires, Inc. These include Timiron~ MP-28 (particle size range 27,000 - 37,000 nm), Timiron~ MP-29 (particle size range 47,000 - 55,000 nm), and Timiron~ MP-24 (particle size range 56,000 - 70,000 nm). Most prefered is Timiron~ MP-24.
Among the suitable iron oxide coated mica platelets are materials available from EM Industires, Inc. These include Coloron a~ Bronze Sparkle (particle size range 28,000 -42,000 nm), Colorona~ Glitter Bronze (particle size range 65,000 - 82,000 nm), Colorona~ Copper Sparkle (particle size range 25,000 - 39,000 nm), and Colorona~ Glitter Copper (particle size range 65,000 - 82,000 nm).
Suitable coatings for mica other than titanium dioxide and iron oxide rnay also achieve the appropriate optical properties required for the present invention. These types of coated micas must also meet the refractive index of at least 1.8. Other coatings include silica on the mica platelets.
Advantageou sly, optional active agents other than conditionin g agents such as emollients or moisturizers defined above may be added to the cleansing composition in a safe and effective amount during formulation to treat the skin during the use of the product. These active ingredients may be advantageously selected from antimicrobi al and antifungal actives, vitamins, anti-acne actives; anti-wrinkle, anti-skin atrophy and skin repair actives; sksn barrier repair actives; non- steroidal cosmetic soothing actives; artificial tanning agents and accelerators; skin lightening actives; sunscreen actives;
sebum stimulators; sebum inhibitors; anti-oxidants; protease inhibitors; skin tightening agents; anti-itch ingredients;
hair growth inhibitors; 5-alpha reductase inhibitors;
desquamatin g enzyme enhancers; anti-glycation agents;
topical anesthetics, or mixtures thereof; and the like.
These active agents may be selected from water-soluble active agents, oil soluble active agents, pharmaceutically-acceptable salts and mixtures thereof. Advantageously the agents will be soluble or dispersible in the cleansing composition. The term "active agent" as used herein, means personal care actives which can be used to deliver a benefit to the skin and/or hair and which generally are not used to confer a condition ing benefit, as is conferred by humectants and emollients pre viously described herein. The term "safe and effective amount" as used herein, means an amount of active agent high enough to modify the condition to be treated or to deli ver the desired skin care benefit, but low enough to avoid serious side effects. The term "benefit,"
as used herein, means the therapeutic, prophylactic, and/or chronic benefits associated with treating a particular condition with one or more of the active agents described herein.
What is a safe and effective amount of the active agent ingredient will vary with the specific active agent, the ability of the act ive to penetrate through the skin, the age, health condit zon, and skin condition of the user, and other like factors. Preferably the composition of the present invention comprise from 0.01 o to 50 0, more preferably from 0.05 o to 25 0, even more preferably 0.1 0 to 10 0, and most preferably 0.1 o to 5 0, by weight of the active agent component.
Anti-acne actives can be effective in treating acne vulgaris, a chroni c disorder of the pilosebaceous follicles.
Non-limiting e~amp 1es of useful anti-acne actives include ~5 the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid and 4 methoxysalicylic acid, and resorcinol;
retinoids such as retinoic acid and its derivatives (e. g., cis and trans); sulfur-containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, mixtures thereof and the like.
Anti-microbial and anti-fungal actives can be effective to prevent the proliferation and growth of bacteria and fungi.
Non-limiting examples of anti-microbial and anti-fungal actives include b-lactam drugs, quinolone drugs, ciprofloxacin, norfloxa cin, tetracycline, erythromycin, amikacin, 2,4,4-trichl oro-2~-hydroxy Biphenyl ether,
3,4,4- trichlorobanili de, phenoxyethanol, triclosan;
triclocarban; and mixtures thereof and the like.
Anti-wrinkle, anti-skin atrophy and skin repair actives can be effective in repleni skiing or rejuvenating the epidermal layer. These actives generally provide these desirable skin care benefits by promoting or maintaining the natural process of desquamation. Non-limiting examples of anti-wrinkle and anti-skin atrophy actives include vitamins, minerals, and skin nutrients such as milk, vitamins A, E, and K; vitamin alkyl esters, including vitamin C alkyl esters; magnesium, calcium, copper, zinc and other metallic components; retinoic acid and its derivatives (e.g., cis and trans); retinal; retinol; retinyl esters such as retinyl acetate, retinyl palmit ate, and retinyl propionate; vitamin B 3 compounds (such as niacinamide and nicotinic acid), alpha hydroxy acids, beta hydroxy acids, e.g. salicylic acid and derivatives thereof (such as 5-octanoyl salicylic acid, heptyloxy 4 salicylic acid, and 4-methoxy salicylic acid);
mixtures thereof and th a like.
Skin barrier repair act Ives are those skin care actives which can help repair and rep lenish the natural moisture barrier function of the epidermis. Non-limiting examples of skin barrier repair actives includ a lipids such as cholesterol, ceramides, sucrose esters and pseudo-ceramides as described in European Patent Specificat ion No. 556,957; ascorbic acid;
biotin; biotin esters; phosph olipids, mixtures thereof, and the like.
Non-steroidal cosmetic,soothi ng actives can be effective in preventing or treating inflammation of the skin. The soothing active enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin t one or color. Non-limiting examples of cosmetic soothing agents include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid der svatives; mixtures thereof and the like. Many of these cosmetic soothing actives are described in U.S. Pat. No. 4,985,459 to Sunshine et al., issued Jan. 15, 1991, incorpo rated by reference herein in its entirety.
Artificial tanning actives can help in simulating a natural suntan by increasing melanin zn the skin or by producing the appearance of increased melan Zn in the skin. Non-limiting examples of artificial tannin g agents and accelerators include dihydroxyacetaone; tyrosine; tyrosine esters such as ~5 ethyl tyrosinate and glucose tyrosinate; mixtures thereof, and the like.
Skin lightening actives can actually decrease the amount of melanin in the skin or provide such an effect by other mechanisms. Non-limiting examples of skin lightening actives useful herein include aloe extract, alpha-glyceryl-Z-ascorbic acid, aminotyroxine, ammonium lactate, glycolic acid, hydroquinone, 4 hydraxyanisole, mixtures thereof, and the like.
Also useful herein are sunscreen a dives. A wide variety of sunscreen agents are described in U.S. Pat. No. 5,087,445, to Haffey et al., issued Feb. 11, 1992; U.S. Pat. No.
5,073,372, to Turner et al., issue d Dec. 17, 1991; U.S. Pat.
No. 5,073,371, to Turner et al. issued Dec. 17, 1991; and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology, all of which are incorporated herein by reference in their entirety. Non-limiting examples of sunscreens which are useful in the compositions of the present invent ion are those selected from octyl methoxyl cinnamate (Parsol MCX) and butyl methoxy benzoylmethane (Parsol 1789), 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N,N -dimethyl-p-aminobenzoate, p- aminobenzoic acid, 2-phenylbenz:imidazole-5-sulfonic acid, oxybenzone, mixtures thereof, and the like.
Sebum stimulators can increase the production of sebum by the sebaceous glands. Non-limiting examples of sebum stimulating actives include bryono lic acid, dehydroetiandrosterone (DHEA), orizanol, mixtures thereof, and the like.
Sebum inhibitors can decrease the production of sebum by the sebaceous glands. Non-limiting examples of useful sebum inhibiting actives include aluminum hydroxy chloride, corticosteroids, dehydroacetic aci d and its salts, dichlorophenyl imidazoldioxolan (available from Elubiol), mixtures thereof, and the like.
Also useful as actives in the present invention are protease inhibitors. Protease inhibitors can be divided into two general classes: the proteinases and the peptidases.
Proteinases act on specific interior peptide bonds of proteins and peptidases act on peptide b ands adjacent to a free amino or carboxyl group on the end of a protein and thus cleave the protein from the outside. The protease inhibitors suitable for use in the present invention include, but are not limited to, protein aces such as serine proteases, metalloproteases, cysteine proteases, and aspartyl protease, and peptidases, such as carboxypepidases, dipeptidases and aminopepidases, mixture s thereof and the like.
Other useful as active ingredients in the present invention are skin tightening agents. Non-limitin g examples of skin tightening agents which are useful in the compositions of the present invention include monomers which can bind a polymer to the skin such as terpolymers of vinylpyrrolidone, (meth)acrylic acid and a hydrophobic monomer comprised of long chain alkyl (meth)acrylates, mixtures thereof, and the like.
Active ingredients in the present invent.i.on may also include anti-itch ingredients. Suitable examples of anti-itch ingredients which are useful in the comp ositions of the present invention include hydrocortisones methdilizine and trimeprazineare, mixtures thereof, and the like.
Non-limiting examples of hair growth inhibitors which are useful in the compositions of the present invent ion include 17 beta estradiol, anti-angiogenic steroids, curcuma extract, cycloxygenase inhibitors, evening primrose oil, linolei c acid and the like. Suitable 5-alpha r eductase inhibit ors such as ethynylestradiol and, genist ine mixtures thereof, and the like.
Non-limiting examples of desquamating enzyme enhancers which are use ~ul in the compositions of the present invention include alanine, aspartic acid, N methyl serine, serine, trimeth~l glycine, mixtures thereof, and the like.
A non-1 zmiting example of an anti-glycation agent which is useful in the compositions of the present invent ion would be Amadorine (available from Barnet Products Distrs butor), and the like .
EXAMPLE S
The invention will now be described in greater detail by way of the following non-limiting examples. The ex~.mples are for illustrative purposes only and not intended to limit the invention in any way. Physical test methods are described below.
Except sn the operating and comparative examples, or where otherwi s a explicitly indicated, all numbers in this description indicating amounts or ratios of mat erials or conditions or reaction, physical properties of materials and/o r use are to be understood as modified by the word "about" .
Where used in the specification, the term "comprising" is intended to include the presence of stated features, rote g ers, steps, components, but not to preclude the presence or addition of one or more features, integer s, step s, components or groups thereof.
All percentages in the specification and examples are intended to be by weight unless stated otherwise.
Examples 1 to 11 (Isotropic Structure) Examples of the inventive cleansing compositions (examples 1 - 7 below) were prepared, and their stability and visual effect on skin and tile substrates after rinse off were compared to non-inventive compositions (examples 8 - 1 1 below). The inventive compositions were found to provide a significant change in skin and tile appearance compare d to the comparative examples.
Examples 1 - 11 Exam Ales Inventive/ Inv.Inv.Inv.Inv.Inv.Inv.Inv.Com Com ComCom com arative Components (/NCI name) (% Active b wt.) Ammonium 5.02 5.024.145.024.875.025.02 4.875.02 Lau I Sulfate (1) Ammonium 3.98 3.983.283.983.863.983.98 3.863.98 Laureth Sulfate (1) Cocamide 0.86 0.860.710.860.840.860.86 0.840.86 MEA
(1) PEG-5 Cocamide0.43 0.430.360.430.420.430.43 0.420.43 (1) Sodium Laureth 10 10.15 Sulfate (2) Cocamidopropyl1.8 2 1.5 1.8 1.5 1.8 0.8 2 1.50.8 Betaine (3) Acrylates 1.2 1.2 1.21.4 1.2 1.2 1.2 1.5 1.2 1.21.5 Co of mer
triclocarban; and mixtures thereof and the like.
Anti-wrinkle, anti-skin atrophy and skin repair actives can be effective in repleni skiing or rejuvenating the epidermal layer. These actives generally provide these desirable skin care benefits by promoting or maintaining the natural process of desquamation. Non-limiting examples of anti-wrinkle and anti-skin atrophy actives include vitamins, minerals, and skin nutrients such as milk, vitamins A, E, and K; vitamin alkyl esters, including vitamin C alkyl esters; magnesium, calcium, copper, zinc and other metallic components; retinoic acid and its derivatives (e.g., cis and trans); retinal; retinol; retinyl esters such as retinyl acetate, retinyl palmit ate, and retinyl propionate; vitamin B 3 compounds (such as niacinamide and nicotinic acid), alpha hydroxy acids, beta hydroxy acids, e.g. salicylic acid and derivatives thereof (such as 5-octanoyl salicylic acid, heptyloxy 4 salicylic acid, and 4-methoxy salicylic acid);
mixtures thereof and th a like.
Skin barrier repair act Ives are those skin care actives which can help repair and rep lenish the natural moisture barrier function of the epidermis. Non-limiting examples of skin barrier repair actives includ a lipids such as cholesterol, ceramides, sucrose esters and pseudo-ceramides as described in European Patent Specificat ion No. 556,957; ascorbic acid;
biotin; biotin esters; phosph olipids, mixtures thereof, and the like.
Non-steroidal cosmetic,soothi ng actives can be effective in preventing or treating inflammation of the skin. The soothing active enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin t one or color. Non-limiting examples of cosmetic soothing agents include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid der svatives; mixtures thereof and the like. Many of these cosmetic soothing actives are described in U.S. Pat. No. 4,985,459 to Sunshine et al., issued Jan. 15, 1991, incorpo rated by reference herein in its entirety.
Artificial tanning actives can help in simulating a natural suntan by increasing melanin zn the skin or by producing the appearance of increased melan Zn in the skin. Non-limiting examples of artificial tannin g agents and accelerators include dihydroxyacetaone; tyrosine; tyrosine esters such as ~5 ethyl tyrosinate and glucose tyrosinate; mixtures thereof, and the like.
Skin lightening actives can actually decrease the amount of melanin in the skin or provide such an effect by other mechanisms. Non-limiting examples of skin lightening actives useful herein include aloe extract, alpha-glyceryl-Z-ascorbic acid, aminotyroxine, ammonium lactate, glycolic acid, hydroquinone, 4 hydraxyanisole, mixtures thereof, and the like.
Also useful herein are sunscreen a dives. A wide variety of sunscreen agents are described in U.S. Pat. No. 5,087,445, to Haffey et al., issued Feb. 11, 1992; U.S. Pat. No.
5,073,372, to Turner et al., issue d Dec. 17, 1991; U.S. Pat.
No. 5,073,371, to Turner et al. issued Dec. 17, 1991; and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology, all of which are incorporated herein by reference in their entirety. Non-limiting examples of sunscreens which are useful in the compositions of the present invent ion are those selected from octyl methoxyl cinnamate (Parsol MCX) and butyl methoxy benzoylmethane (Parsol 1789), 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N,N -dimethyl-p-aminobenzoate, p- aminobenzoic acid, 2-phenylbenz:imidazole-5-sulfonic acid, oxybenzone, mixtures thereof, and the like.
Sebum stimulators can increase the production of sebum by the sebaceous glands. Non-limiting examples of sebum stimulating actives include bryono lic acid, dehydroetiandrosterone (DHEA), orizanol, mixtures thereof, and the like.
Sebum inhibitors can decrease the production of sebum by the sebaceous glands. Non-limiting examples of useful sebum inhibiting actives include aluminum hydroxy chloride, corticosteroids, dehydroacetic aci d and its salts, dichlorophenyl imidazoldioxolan (available from Elubiol), mixtures thereof, and the like.
Also useful as actives in the present invention are protease inhibitors. Protease inhibitors can be divided into two general classes: the proteinases and the peptidases.
Proteinases act on specific interior peptide bonds of proteins and peptidases act on peptide b ands adjacent to a free amino or carboxyl group on the end of a protein and thus cleave the protein from the outside. The protease inhibitors suitable for use in the present invention include, but are not limited to, protein aces such as serine proteases, metalloproteases, cysteine proteases, and aspartyl protease, and peptidases, such as carboxypepidases, dipeptidases and aminopepidases, mixture s thereof and the like.
Other useful as active ingredients in the present invention are skin tightening agents. Non-limitin g examples of skin tightening agents which are useful in the compositions of the present invention include monomers which can bind a polymer to the skin such as terpolymers of vinylpyrrolidone, (meth)acrylic acid and a hydrophobic monomer comprised of long chain alkyl (meth)acrylates, mixtures thereof, and the like.
Active ingredients in the present invent.i.on may also include anti-itch ingredients. Suitable examples of anti-itch ingredients which are useful in the comp ositions of the present invention include hydrocortisones methdilizine and trimeprazineare, mixtures thereof, and the like.
Non-limiting examples of hair growth inhibitors which are useful in the compositions of the present invent ion include 17 beta estradiol, anti-angiogenic steroids, curcuma extract, cycloxygenase inhibitors, evening primrose oil, linolei c acid and the like. Suitable 5-alpha r eductase inhibit ors such as ethynylestradiol and, genist ine mixtures thereof, and the like.
Non-limiting examples of desquamating enzyme enhancers which are use ~ul in the compositions of the present invention include alanine, aspartic acid, N methyl serine, serine, trimeth~l glycine, mixtures thereof, and the like.
A non-1 zmiting example of an anti-glycation agent which is useful in the compositions of the present invent ion would be Amadorine (available from Barnet Products Distrs butor), and the like .
EXAMPLE S
The invention will now be described in greater detail by way of the following non-limiting examples. The ex~.mples are for illustrative purposes only and not intended to limit the invention in any way. Physical test methods are described below.
Except sn the operating and comparative examples, or where otherwi s a explicitly indicated, all numbers in this description indicating amounts or ratios of mat erials or conditions or reaction, physical properties of materials and/o r use are to be understood as modified by the word "about" .
Where used in the specification, the term "comprising" is intended to include the presence of stated features, rote g ers, steps, components, but not to preclude the presence or addition of one or more features, integer s, step s, components or groups thereof.
All percentages in the specification and examples are intended to be by weight unless stated otherwise.
Examples 1 to 11 (Isotropic Structure) Examples of the inventive cleansing compositions (examples 1 - 7 below) were prepared, and their stability and visual effect on skin and tile substrates after rinse off were compared to non-inventive compositions (examples 8 - 1 1 below). The inventive compositions were found to provide a significant change in skin and tile appearance compare d to the comparative examples.
Examples 1 - 11 Exam Ales Inventive/ Inv.Inv.Inv.Inv.Inv.Inv.Inv.Com Com ComCom com arative Components (/NCI name) (% Active b wt.) Ammonium 5.02 5.024.145.024.875.025.02 4.875.02 Lau I Sulfate (1) Ammonium 3.98 3.983.283.983.863.983.98 3.863.98 Laureth Sulfate (1) Cocamide 0.86 0.860.710.860.840.860.86 0.840.86 MEA
(1) PEG-5 Cocamide0.43 0.430.360.430.420.430.43 0.420.43 (1) Sodium Laureth 10 10.15 Sulfate (2) Cocamidopropyl1.8 2 1.5 1.8 1.5 1.8 0.8 2 1.50.8 Betaine (3) Acrylates 1.2 1.2 1.21.4 1.2 1.2 1.2 1.5 1.2 1.21.5 Co of mer
(4) Guar 0.3 0.3 0.3 0.3 0.3 0.3 Hydroxypropyltri monium chloride
(5) Polyquaternium-6 1.5 (6 Polyquaternium- 0.1 0.1 (7) Wheatgermamido 0.2 propyl dimethylamine hydrolized wheat protein (8) PEG-14M 0.15 (9) PEG-45M 0.05 (10) Mica and 0.5 0.5 0.450.450.9 0.45 Ti02 (10-150Nm)(11) Mica and 0.050.050.1 0.050.5 Ti02 and iron oxide (10-150~tm)(12) Mica and 0.05 Ti02 (<50 m)(13) Mica and 0.01 Ti02 and iron oxide (10-150pm)(14) Mica and 0.07 Ti02 and iron oxide (5-100Nm)(15) Mica and 0.5 Ti02 (5-25 m)(16) Mica and 0.5 Ti02 and triethoxy ca r I Isilane(17) Pol eth lene (18) GI cerin 1 1 1 0.5 1 1.251 0.5 1.250.5 Shea Butter 0.01 0.01 Divinyldimethicone 0.9 0.9 l Dimethicone copol mer Prop lene 1.75 1.1 0.15 0.65 I col Sodium chloride 0.8 0.75 Ammonium 1.10.2 0.2 0.5 chloride Methylchloroiso-3 3 3 3 3 3 3 3 3 thiazolinone and methylisothiazol-inone (x 10-4) DMDM H dantoin 0.1 Sodium Benzoate 0.5 Tetrasodium 2 2 2 2 2 2 2 2 2 2 EDTA (x 10-Z) Citric acid 0.4 Sodium hydroxide1 0.40.2 0.2 1 1 2 0.751 1.5 (x 10-~ ) Benzo henone-4 0.1 Fra rance 1.3 0.9 0.60.8 0.6 0.6 0.6 1.3 0.9 0.60.6 Water q.s.q.s.q.s,q.s.q.s.q.s.q.s.q.s.q.s.q.s.q.s.
to to to to to to to to to to to 100 100 100100 '100100 100 100 100 100100 Pro erties Viscosity 2.3 1.971.5 2.352.34 1.9 0.942.451.45 (x 10"), cps (21 ) H (25C 5.5 5.5 5.56.6 5.5 6.5 5.4 6.3 4.6 6.76.6 Stability yes yes yesyes yes yes yes yes yes no yes (yes/no) (22) (22a) (22a) (22a) Visual effectYes,Yes,Yes,Yes,Yes,Yes,No, No, No, No,No, determinationcon con labcon !ab tile/lab tile/con tiletile/
(yes/no, lab lab lab method used (23 Glitter count (24) 5 5~ ~~
Notes (1)ALMEO blend Stepan (2)EMAL 270 Huntsman (3)Tegobetaine F Goldschmidt (4)Aqua SF-1 Noveon (5)Jaguar Rhodia
to to to to to to to to to to to 100 100 100100 '100100 100 100 100 100100 Pro erties Viscosity 2.3 1.971.5 2.352.34 1.9 0.942.451.45 (x 10"), cps (21 ) H (25C 5.5 5.5 5.56.6 5.5 6.5 5.4 6.3 4.6 6.76.6 Stability yes yes yesyes yes yes yes yes yes no yes (yes/no) (22) (22a) (22a) (22a) Visual effectYes,Yes,Yes,Yes,Yes,Yes,No, No, No, No,No, determinationcon con labcon !ab tile/lab tile/con tiletile/
(yes/no, lab lab lab method used (23 Glitter count (24) 5 5~ ~~
Notes (1)ALMEO blend Stepan (2)EMAL 270 Huntsman (3)Tegobetaine F Goldschmidt (4)Aqua SF-1 Noveon (5)Jaguar Rhodia
(6)Merquat 100 Ondeo Nalco
(7)Polymer JR-400 Amerchol
(8)Mackpro WWP McIntyre
(9)Polyox WSR N-3000 Amerchol
(10)Polyox WSR N-60K Amerchol
(11)Timiron MP-149 EMD Chemicals
(12)Colorona Glitter Copper EMD Chemicals
(13)Flamenco Ultra Sparkle 4500 Englehard
(14)Timiron MP-24 EMD Chemicals
(15)Timiron MP-25 EMD Chemicals
(16)Timiron MP-1001 EMD Chemicals
(17)Timiron MP-1001AS Cardre
(18)Microthene MN711/20 Equistar
(19)Cetiol SB-45 Cognis
(20)HMW 2220 Nonionic Emulsion Dow Corning
(21) Brookfield RVDV-I+, CP 41, 0.5rpm; 25°C.
Viscosity is adjusted by adding salt (s) such as ammonium chloride or sulfate or sodium chloride to increase viscosity and propylene gL ycol to decrease viscosity as the case may be.
Viscosity is adjusted by adding salt (s) such as ammonium chloride or sulfate or sodium chloride to increase viscosity and propylene gL ycol to decrease viscosity as the case may be.
(22) Stability test (see method beL ow) (22a) Evaluated for stability only at room temperature, and only by visual ins pection (not viscosity) and were stable.
(23) Yes/No: see criteria in method discussion below.
Methods: con = consumer evaluation, lab = lab evaluation, tile = tile evaluation, tile/lab = tile and lab evaluation
Methods: con = consumer evaluation, lab = lab evaluation, tile = tile evaluation, tile/lab = tile and lab evaluation
(24) See glitter count method below.
Example preparation details:
Examples 1, 6, and 8 Add water (49 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add shea butter Add betaine Add quench water (15 % of batch) Add NaOH soln Add Jaguar submix (Jaguar, glycerin, propylene glycol) Add Timiron submix (Timiron + 2 % water) Add Versene 100 Adjust pH to 5.5 At 45°C, add Kathon At 40°C, add fragrance Adjust viscosity to 18,000-25,000 cps Example 2 Add water (37.6 %) and start heating to 60°C
Add Aqua SF1 polymer Add EDTA
Add betaine Add SLES at 60°C
Mix until homogeneous Add water (30 %) Add NaCI
Add glycerin/Jaguar submix Add NaOH
Add Timiron/water premix (Timiron + 2 % water) Under 45°C add Glydant At 40°C, add fragrance Adjust pH to 5.5 Adjust viscosity to 10,000 cps Example 3 Add water (37.6 %) and start heating to 60°C
Add Aqua SF1 polymer Add EDTA
Add betaine Add SLES at 60°C
Mix until homogeneous Add water (30 %) Add NaCI
Add NaOH
Add Timiron/water premix (Timiron + 2 % water) Under 45°C add Glydant At 40°C, add fragrance Adjust pH to 5.5 Adjust viscosity to 10,000 cps Add polyethylene particles Example 4 Add water (47 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add glycerin Add Versene 100 Add water (15 %) Add betainelMerquat 100 submix Slowly add Timiron/water submix (Timiron + 2 °/~ water) Adjust pH to 5.5 At 45°C, add Kathon At 40°C, add fragrance Adjust viscosity to 18,000-25,000 cps Example 5 Add water (50 %) Add Aqua SF-1 Add Almeo Begin to heat to 65°C
Once at Temp and dissolved add all of NaOH
Add Glycerin/Polyox submix mix Add Versene Add Remaining water Add Betaine Add Mackpro Add Timiron/water submix (Timiron + 2 % water) Let cool At 45°C, add Kathon At 40°C, add fragrance Example 7 Add water (47 %) and start heating to 60°C
Add Aqua SF1 polymer Add ALMEO blend; mix 10-20 min Add glycerin/Polyox submix (0.5 % glycerin) At 60°C and dissolved add NaOH
Add Versene Add water (20 %) Add betaine Add Jaguar/0.75 % glycerin/propylene glycol premix Let cool At 45°C add Kathon Add Timiron premix At 40°C add fragrance Add HMW 2220 Adjust pH to 6.5 Adjust viscosity to 18,000-24,000 cps Examples 9 and 12 Add water (56 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add shea butter Add Versene 100 Add quench water (14 %) Add betaine Add glycerin Add Uvinul At 45°C, add Kathon At 40°C, add fragrance/polymer JR400 submix Add NaOH solution to pH 6.5 Add Flamencolwater submix (2 % water) Adjust viscosity to 14,000-19,000 cps Example 10 Add water (39 %) and start heating to 60°C
Add Aqua SF1 polymer Add betaine Add SLES
Mix until homogeneous Add water (30 %) Add NaOH solution Add NaCI solution Add Timiron/water premix (2 % water) At 45°C, add sodium benzoate Add citric acid Add Euperlan Add fragrance Adjust pH to 4.7 Adjust viscosity to 10,000 cps Example 11 Add water (47 %) and start heating to 60°C
Add Aqua SF1 polymer Add ALMEO blend; mix 10-20 min Add glycerin (0.5 %) At 60°C and dissolved add NaOH
Add Versene Add water (20 %) Add betaine Add Jaguar/0.75 % glycerin/propylene glycol premix At 45°C add Kathon At 40°C add fragrance Add HMW 2220/Timiron premix Adjust pH to 6.5 Adjust viscosity to 18,000-24,000 cps Examples 1A to 7A (Lamellar Structure) Examples of the inventive cleansing compositions (examples 1a - 5a below) were prepared and their stability and visual effect on skin and tile substrates after rinse off were compared to non-inventive compositions (examples 6a - 7a below). The inventive compositions were found to provide a significant change in skin and tile appearance compared to the comparative examples.
Examples la - 7a Examples 1a 2a 3a 4a 5a 6a 7a Inventive/ComparativeInv. Inv. Inv. Inv. Inv. Comp.Comp.
Component (INCI
name) (% Active by wt.) Ammonium Lauryl 3.9 3.9 3.9 3.9 3.9 3.9 3.9 Sulfate (1) Ammonium Laureth 3.1 3.1 3.1 3.1 3.1 3.1 3.1 Sulfate (1) Cocamide MEA (1 0.67 0.67 0.67 0.67 0.67 0.67 0.67 ) PEG-5 Cocamide (1) 0.33 0.33 0.33 0.33 0.33 0.33 0.33 Cocamidopropyl Betaine4 4 4 4 4 4 4 (2) Cocamide MEA (3) 1.05 1 1.05 1.05 1.05 1.05 1.05 Laurie Acid (4) 1.2 4 2.5 2.5 1 2.5 2.5 Guar Hydroxpropyl 0.7 0.5 0.7 0.7 0.7 0.7 0.7 Trimonium Chloride (5) Glycerin 5.7 2 5.7 5.7 5.7 5.7 5.7 Sunflower Seed Oil 21.3 2.5 5 5 21.3 5 5 Petrolatum (5a) 3.7 2.5 3.7 3.7 3.7 3.7 3.7 Cholesterol/lanolin0.46 0.46 alcohol (6) Mica and Ti02 (7) 1 0.45 0.5 1 Mica and Ti02 and 0.05 0.5 iron oxide 8) Bismuth Oxychloride 1 and eth Ihex I h drox stearate (9) Mica and Ti02 and 1 triethox ca r I
Isilane (10) DMDM Hydantoin 0.0550.0550.0550.0550.0550.0550.055 Tetrasodium EDTA 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Etidronic Acid 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Fragrance 1 0.6 1 1 1 1 1 DI Water to to to to to to to Properties:
Viscosity (x 104) 8.64 7.25 6.76 9.56 (cps) 25C
(11) Viscosity (x 104) 1.186 cps 25C
(12 pH (25C) 5.5 5.5 5.5 5.6 5.7 5.5 5.5 Stability (13) stablestablestablestablestablestablestable (13a)(13a) Visual effect determinationYes, Yes, Yes, Yes, Yes, No, No, ( es/no, method con lab tile tile lab lab lab used (14) Dotes (1) AZMEO blend Stepan (2) Tegobetaine F Goldschmidt (3) Mackamide CMA McIntyre (4) Prifrac 2922 Uniqema (5) Jaguar C13S Rhodia (5a) G-1937 Hard Penreco (6) Super Hartolan Croda (7)Timiron MP-149 (10-150um) EMD Chemicals (8) Colorona Glitter EMD Chemicals Copper(10-150um) (9) Biron hiquid Silver EMD Chemicals (10) Timiron MP-1001AS Cardre (11) Brookfield RV DV-II+, T-bar, 0.5 rpm.
(12) Brookfield RVDV-I+, CP 41, 0.5 rpm.
(13) Stability test (see method below) (13a) Evaluated for stability only at room temperature, and only by visual inspection (not viscosity), and were stable.
(14) Yes/No: see criteria in method discussion below.
Methods: con = consumer evaluation, lab = lab evaluation, tile = tile evaluation, tile/lab = tile and lab evaluation (see below for methods) (15) See glitter count method below.
Example preparation details Examples 1 a, 5a Add sunflower oil (14,3 %) Add Super Hartolan and CMEA
Add lauric acid and petrolatum Heat to 70°C until all dissolved Add glycerin Stop heating Add water (7 %) Add betaine Add ALMEO blend; mix until smooth Add rest of water (27 %) Add particles Add Jaguar/? % oil blend Add EDTA and EHDP
Add Glydant Add fragrance Mix until cools to 35°C
Examples 2a, 3a, 4a, 6a, 7a Add water (40 %) Add betaine; start heating to 70°C
Add CMEA at 60°C
Mix until dissolved Add ALMEO; mix until smooth Stop heating at 70°C
Heat premix to 70°C
(premix = oil, lauric acid, petrolatum, Timiron) When premix is at 70°C, add to batch Add rest of water (17 %) Add Jaguar/glycerin blend Add EDTA and EHDP
Add Glydant Add fragrance Methods Stabilitv Method Samples are stored at the following conditions and evaluated at the following time points.
Condition Time Evaluations Evaluation Points Room 12 weeks Viscosity, VisualInitial Temperature 1 day 1, 2, 4, 8, weeks 40C 12 weeks Visual only 1, 2, 4, 8, weeks 50C 1 week Viscosity, Visual1 week -9C/25C cycle 3 cycles (6 Viscosity, Visual1 week days) (24 hours at each temp.) Viscosity: Measured by the method indicated for each example Visual evaluation: color, odor, and appearance A sample is considered stable if its viscosity and visual evaluation do not change significantly (i.e. greater than 20 o relative) from the initial measurements at all conditions.
Tile evaluation method Prepare clay tiles with tan colored Sculpey II Polymer Clay (Polyform Products, Elk Grove, LL) by kneading clay, then rolling to a uniform thickness (2-3mm) with a rolling pin.
Cut 1'° by 1'° squares and press down 100 grain sandpaper on each square to make an even impression of the sandpaper on the clay. Bake for 15 minutes at 120°C and cool.
Wash tiles by placing 0.1g product on a wet tile. Add 0.2g water and rub for 15 seconds with a latex gloved finger.
Rinse with tap water at 35-45°C at a flow rate of 13-14 ml/sec, holding the tile 5 cm away at a 45-degree angle.
Blot once with a paper towel and air dry for 15 minutes.
Visually evaluate the quantity of optical particles left on the tiles.
Yes = At least 15 sparkles visible on a tile.
No = less than this value.
Hand wash (Consumer evaluation) method Give the product to naive consumers to use according to the following instructions: "Use similar to your regular body was h, applying to wet skin, sponge, washcloth, or pouf.
Wor k into a lather and rinse.°' Ask consumers if they saw any change in the appearance of their skin, e.g. whether the it skin looked radiant, shimmery, lustrous, glowing, etc.
Naive consumers are defined as consumers that have not been trained in any way - in the use of the product or in what to loo k for on the skin.
Yes - at least 51 0 of consumers report seeing a visual change .
No - less than this value.
Hand wash (lab evaluation) method Dispense approximately 1.5g product on wet hands. Rub hands together to generate lather, adding water as needed. Rinse hands under running water at 35-45°C until hands feel clean.
Pat dry with paper towel. Inspect hands visually for opt ical particles left behind.
Yes - At least 5 sparkles/cm2 visible on hands.
No - less than this value.
Til e/lab evaluation method is a combination of the Tile evaluation method and the lab evaulation method.
In- vitro Visual Assessment Protocol (Porcine/pia skin assa Take a piece of black porcine skin (L= 40 ~ 3) with the dimensions of 5.0 cm x 10.0 cm and mount it on a black background paper card. Initial measurements are made of the untreated skin. The mounted skin is then washed 1 to 2 minutes with "normal" rubbing with the composition to be tested and rinsed for 1/2 minute with 45°C tap water. After 2 hours of drying at 25°C, the final measurements for color L, a*, b*; reflectivity and opacity are made.
Color Measurements The initial and final color measurements of porcine or in-vivo human skin are made with a Hunter Lab spectracolormeter using a 0° light source and 45° detector geometry. The spectracolormeter is calibrated with the appropriate black and white standards. Measurements are made before and after the wash treatment. Three measurements are made each time and averaged. The values obtained are L, a*, b*, which come from the La*b ~ color space representation.
Opacity Determination The opacity of the skin treated by the cleansing composition can be derive d from the hunter Lab color measurements. The opacity contrast value is calculated from the delta L (which is the change in whiteness after deposition) divided by 60 (which is the difference in L value of the skin and a pure white color).
Reflectance o r Radiance Determination The initial and ffi nal reflectance/radiance measurement of porcine or in-viva human skin is made with a glossmeter before and after treatment with the cleansing composition.
The glossmeter is first set with both the detector and light source at 85° from normal. Then the glossmeter is calibrated with an appropriat a reflection standard. Measurements are made before and after application and rinsing off of the cleansing composition and the percent difference calculated.
Since a noticeabl a change in the skin when treated with the inventive composition may provide only scattered areas of skin appearance enhancement (such as point sparkle, glitter, etc.) instead of a continuous change over a wider expanse of the skin better suited to instrumental analysis using the glossmeter etc; for the purposes of defining the level of skin appearance change required to be shown for the inventive composition, a "yes" result in either the Tile method, the Consumer method, the Hand wash (lab) method, or any combination thereof is to be considered equivalent to at least a 5 o change in reflectivity when the inventive cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol.
In-viva Glitter C aunt Glitter count is a useful indicator regarding deposition but must be supplemented with other visual appearance methods to establish whether a sufficient change in visual appearance exists.
Method Wash a 5 cm by 10 cm sect ion of an inside forearm of a human panelist with the cleansing composition for 1 to 2 minutes with "normal" rubbing and rinse for 1/2 minute with 45°C tap water. Let air dry for 20 min (no wiping) at 25°C. Then, under an intense light source or sunlight, count the number of sparkles seen in the washed area. The minimum number of sparkles counted consider ed for a 'good" deposition is 2.
The results are compared to a control consisting of the surfactant system and dei onized water alone. The glitter count of the control is zero (i.e. no observable deposition).
Cone and Plate Viscosity Measurement Scope This method covers the measurement of the viscosity of the isotropic phase cleansing composition.
Apparatus Brookfield Cone and Plate DV-II+ Viscometer.
Spindle 541.
Procedure 1. Turn on Water Bath attached to the sample cup of the viscometer. Make sur a that it is set for 25°C. Allow temperature readout t o stabilize at 25°C before proceeding.
2. With the power to the ~riscometer off, remove the spindle (S41) by turning count erclockwise.
3. Turn the power on and press any key as requested to autozero the viscomete r.
4. When the autozero function is complete, replace the spindle (turning clockwise) and press any key.
5. Attach the sample cup. Using the up/down arrow keys, slowly change the spee d to 10 rpm and press the SET
SPEED key. Use the SELECT DISPLAY key so that the display is in o mode.' 6. Turn the motor on. If the display jumps to 0.4 0 or higher or will not set t le to 0 ~0.1 0, turn the adjustment ring clockwise until it does.
7. Rotate the adjustment ring counterclockwise until the reading is fluctuating between 0.0 and 1.0 0. The fluctuation must occur approximately every 6 seconds.
8. Turn the adjustment ring clockwise exactly the width of one division from the setting reached in step 7.
9. Turn the motor off. Using the up/down arrow keys, slowly change the speed to 0.5 rpm and press the SET
SPEED key. Use the SELECT DISPLAY so that the display is in cP.
10. Place 2 ~ O.lg of product to be measured into the sample cup. Attach the cup to the viscometer.
11. Allow the product to remain in the cup with the motor OFF for 2 minutes.
12. Turn the motor ON and allow the spindle to turn for 2 minutes before noting the reading on the display.
T- bar Viscosity Measurement Scope Th is method covers the measurement of the viscosity of the ordered liquid crystalline cleansing composition.
Apparatus Br ookfield RVT Viscometer with Helipath Accessory.
Clzuck, weight and closer assembly for T-bar attachment.
T-bar Spindle A.
PL astic cups diameter greater than 2.5 inches.
n~.~.....~"~.~
1. Verify that the viscometer and the helipath stand are level by referring to the bubble levels on the back of the instrument.
2. Connect the chuck/closer/weight assembly to the Viscometer. (Note the left-hand coupling threads).
3. Clean Spindle A with deionized water and pat dry with a Kimwipe sheet. Slide the spindle in the closer and tighten.
4. Set the rotational speed at 0.5 RPM. In case of a digital viscometer (DV) select the o mode and press autozero with the motor switch on.
5. Place the product in a plastic cup with inner diameter of greater than 2.5 inches. The height of the product in the cup should be at least 3 inches. The temperature of the product should be 25°C.
6. Lower the spindle into the product (~1/4 inches). Set the adjustable stops of the helipath stand so that the spindle does not touch the bottom of the plastic cup or come out of the sample.
7. Start the viscometer and allow the dial to make one or two revolutions before turning on the Helipath stand.
Note the dial reading as the helipath stand passes the middle of its downward traverse.
8. Multiply the dial reading biz a factor of 4,000 and report the viscosity reading in cps.
While this invention has been described with respect to particular embodiments thereof, it is apparent that numerous other forms and modifications o ~ the invention will be obvious to those skilled in the art. The appended claims and this invention generally sh~uld be construed to cover all such obvious forms and modifications which are within the true spirit and scope of the present invention.
Example preparation details:
Examples 1, 6, and 8 Add water (49 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add shea butter Add betaine Add quench water (15 % of batch) Add NaOH soln Add Jaguar submix (Jaguar, glycerin, propylene glycol) Add Timiron submix (Timiron + 2 % water) Add Versene 100 Adjust pH to 5.5 At 45°C, add Kathon At 40°C, add fragrance Adjust viscosity to 18,000-25,000 cps Example 2 Add water (37.6 %) and start heating to 60°C
Add Aqua SF1 polymer Add EDTA
Add betaine Add SLES at 60°C
Mix until homogeneous Add water (30 %) Add NaCI
Add glycerin/Jaguar submix Add NaOH
Add Timiron/water premix (Timiron + 2 % water) Under 45°C add Glydant At 40°C, add fragrance Adjust pH to 5.5 Adjust viscosity to 10,000 cps Example 3 Add water (37.6 %) and start heating to 60°C
Add Aqua SF1 polymer Add EDTA
Add betaine Add SLES at 60°C
Mix until homogeneous Add water (30 %) Add NaCI
Add NaOH
Add Timiron/water premix (Timiron + 2 % water) Under 45°C add Glydant At 40°C, add fragrance Adjust pH to 5.5 Adjust viscosity to 10,000 cps Add polyethylene particles Example 4 Add water (47 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add glycerin Add Versene 100 Add water (15 %) Add betainelMerquat 100 submix Slowly add Timiron/water submix (Timiron + 2 °/~ water) Adjust pH to 5.5 At 45°C, add Kathon At 40°C, add fragrance Adjust viscosity to 18,000-25,000 cps Example 5 Add water (50 %) Add Aqua SF-1 Add Almeo Begin to heat to 65°C
Once at Temp and dissolved add all of NaOH
Add Glycerin/Polyox submix mix Add Versene Add Remaining water Add Betaine Add Mackpro Add Timiron/water submix (Timiron + 2 % water) Let cool At 45°C, add Kathon At 40°C, add fragrance Example 7 Add water (47 %) and start heating to 60°C
Add Aqua SF1 polymer Add ALMEO blend; mix 10-20 min Add glycerin/Polyox submix (0.5 % glycerin) At 60°C and dissolved add NaOH
Add Versene Add water (20 %) Add betaine Add Jaguar/0.75 % glycerin/propylene glycol premix Let cool At 45°C add Kathon Add Timiron premix At 40°C add fragrance Add HMW 2220 Adjust pH to 6.5 Adjust viscosity to 18,000-24,000 cps Examples 9 and 12 Add water (56 %) and start heating to 55°C
Add Aqua SF1 polymer At 55°C, add ALMEO blend; mix 10-20 min Add shea butter Add Versene 100 Add quench water (14 %) Add betaine Add glycerin Add Uvinul At 45°C, add Kathon At 40°C, add fragrance/polymer JR400 submix Add NaOH solution to pH 6.5 Add Flamencolwater submix (2 % water) Adjust viscosity to 14,000-19,000 cps Example 10 Add water (39 %) and start heating to 60°C
Add Aqua SF1 polymer Add betaine Add SLES
Mix until homogeneous Add water (30 %) Add NaOH solution Add NaCI solution Add Timiron/water premix (2 % water) At 45°C, add sodium benzoate Add citric acid Add Euperlan Add fragrance Adjust pH to 4.7 Adjust viscosity to 10,000 cps Example 11 Add water (47 %) and start heating to 60°C
Add Aqua SF1 polymer Add ALMEO blend; mix 10-20 min Add glycerin (0.5 %) At 60°C and dissolved add NaOH
Add Versene Add water (20 %) Add betaine Add Jaguar/0.75 % glycerin/propylene glycol premix At 45°C add Kathon At 40°C add fragrance Add HMW 2220/Timiron premix Adjust pH to 6.5 Adjust viscosity to 18,000-24,000 cps Examples 1A to 7A (Lamellar Structure) Examples of the inventive cleansing compositions (examples 1a - 5a below) were prepared and their stability and visual effect on skin and tile substrates after rinse off were compared to non-inventive compositions (examples 6a - 7a below). The inventive compositions were found to provide a significant change in skin and tile appearance compared to the comparative examples.
Examples la - 7a Examples 1a 2a 3a 4a 5a 6a 7a Inventive/ComparativeInv. Inv. Inv. Inv. Inv. Comp.Comp.
Component (INCI
name) (% Active by wt.) Ammonium Lauryl 3.9 3.9 3.9 3.9 3.9 3.9 3.9 Sulfate (1) Ammonium Laureth 3.1 3.1 3.1 3.1 3.1 3.1 3.1 Sulfate (1) Cocamide MEA (1 0.67 0.67 0.67 0.67 0.67 0.67 0.67 ) PEG-5 Cocamide (1) 0.33 0.33 0.33 0.33 0.33 0.33 0.33 Cocamidopropyl Betaine4 4 4 4 4 4 4 (2) Cocamide MEA (3) 1.05 1 1.05 1.05 1.05 1.05 1.05 Laurie Acid (4) 1.2 4 2.5 2.5 1 2.5 2.5 Guar Hydroxpropyl 0.7 0.5 0.7 0.7 0.7 0.7 0.7 Trimonium Chloride (5) Glycerin 5.7 2 5.7 5.7 5.7 5.7 5.7 Sunflower Seed Oil 21.3 2.5 5 5 21.3 5 5 Petrolatum (5a) 3.7 2.5 3.7 3.7 3.7 3.7 3.7 Cholesterol/lanolin0.46 0.46 alcohol (6) Mica and Ti02 (7) 1 0.45 0.5 1 Mica and Ti02 and 0.05 0.5 iron oxide 8) Bismuth Oxychloride 1 and eth Ihex I h drox stearate (9) Mica and Ti02 and 1 triethox ca r I
Isilane (10) DMDM Hydantoin 0.0550.0550.0550.0550.0550.0550.055 Tetrasodium EDTA 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Etidronic Acid 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Fragrance 1 0.6 1 1 1 1 1 DI Water to to to to to to to Properties:
Viscosity (x 104) 8.64 7.25 6.76 9.56 (cps) 25C
(11) Viscosity (x 104) 1.186 cps 25C
(12 pH (25C) 5.5 5.5 5.5 5.6 5.7 5.5 5.5 Stability (13) stablestablestablestablestablestablestable (13a)(13a) Visual effect determinationYes, Yes, Yes, Yes, Yes, No, No, ( es/no, method con lab tile tile lab lab lab used (14) Dotes (1) AZMEO blend Stepan (2) Tegobetaine F Goldschmidt (3) Mackamide CMA McIntyre (4) Prifrac 2922 Uniqema (5) Jaguar C13S Rhodia (5a) G-1937 Hard Penreco (6) Super Hartolan Croda (7)Timiron MP-149 (10-150um) EMD Chemicals (8) Colorona Glitter EMD Chemicals Copper(10-150um) (9) Biron hiquid Silver EMD Chemicals (10) Timiron MP-1001AS Cardre (11) Brookfield RV DV-II+, T-bar, 0.5 rpm.
(12) Brookfield RVDV-I+, CP 41, 0.5 rpm.
(13) Stability test (see method below) (13a) Evaluated for stability only at room temperature, and only by visual inspection (not viscosity), and were stable.
(14) Yes/No: see criteria in method discussion below.
Methods: con = consumer evaluation, lab = lab evaluation, tile = tile evaluation, tile/lab = tile and lab evaluation (see below for methods) (15) See glitter count method below.
Example preparation details Examples 1 a, 5a Add sunflower oil (14,3 %) Add Super Hartolan and CMEA
Add lauric acid and petrolatum Heat to 70°C until all dissolved Add glycerin Stop heating Add water (7 %) Add betaine Add ALMEO blend; mix until smooth Add rest of water (27 %) Add particles Add Jaguar/? % oil blend Add EDTA and EHDP
Add Glydant Add fragrance Mix until cools to 35°C
Examples 2a, 3a, 4a, 6a, 7a Add water (40 %) Add betaine; start heating to 70°C
Add CMEA at 60°C
Mix until dissolved Add ALMEO; mix until smooth Stop heating at 70°C
Heat premix to 70°C
(premix = oil, lauric acid, petrolatum, Timiron) When premix is at 70°C, add to batch Add rest of water (17 %) Add Jaguar/glycerin blend Add EDTA and EHDP
Add Glydant Add fragrance Methods Stabilitv Method Samples are stored at the following conditions and evaluated at the following time points.
Condition Time Evaluations Evaluation Points Room 12 weeks Viscosity, VisualInitial Temperature 1 day 1, 2, 4, 8, weeks 40C 12 weeks Visual only 1, 2, 4, 8, weeks 50C 1 week Viscosity, Visual1 week -9C/25C cycle 3 cycles (6 Viscosity, Visual1 week days) (24 hours at each temp.) Viscosity: Measured by the method indicated for each example Visual evaluation: color, odor, and appearance A sample is considered stable if its viscosity and visual evaluation do not change significantly (i.e. greater than 20 o relative) from the initial measurements at all conditions.
Tile evaluation method Prepare clay tiles with tan colored Sculpey II Polymer Clay (Polyform Products, Elk Grove, LL) by kneading clay, then rolling to a uniform thickness (2-3mm) with a rolling pin.
Cut 1'° by 1'° squares and press down 100 grain sandpaper on each square to make an even impression of the sandpaper on the clay. Bake for 15 minutes at 120°C and cool.
Wash tiles by placing 0.1g product on a wet tile. Add 0.2g water and rub for 15 seconds with a latex gloved finger.
Rinse with tap water at 35-45°C at a flow rate of 13-14 ml/sec, holding the tile 5 cm away at a 45-degree angle.
Blot once with a paper towel and air dry for 15 minutes.
Visually evaluate the quantity of optical particles left on the tiles.
Yes = At least 15 sparkles visible on a tile.
No = less than this value.
Hand wash (Consumer evaluation) method Give the product to naive consumers to use according to the following instructions: "Use similar to your regular body was h, applying to wet skin, sponge, washcloth, or pouf.
Wor k into a lather and rinse.°' Ask consumers if they saw any change in the appearance of their skin, e.g. whether the it skin looked radiant, shimmery, lustrous, glowing, etc.
Naive consumers are defined as consumers that have not been trained in any way - in the use of the product or in what to loo k for on the skin.
Yes - at least 51 0 of consumers report seeing a visual change .
No - less than this value.
Hand wash (lab evaluation) method Dispense approximately 1.5g product on wet hands. Rub hands together to generate lather, adding water as needed. Rinse hands under running water at 35-45°C until hands feel clean.
Pat dry with paper towel. Inspect hands visually for opt ical particles left behind.
Yes - At least 5 sparkles/cm2 visible on hands.
No - less than this value.
Til e/lab evaluation method is a combination of the Tile evaluation method and the lab evaulation method.
In- vitro Visual Assessment Protocol (Porcine/pia skin assa Take a piece of black porcine skin (L= 40 ~ 3) with the dimensions of 5.0 cm x 10.0 cm and mount it on a black background paper card. Initial measurements are made of the untreated skin. The mounted skin is then washed 1 to 2 minutes with "normal" rubbing with the composition to be tested and rinsed for 1/2 minute with 45°C tap water. After 2 hours of drying at 25°C, the final measurements for color L, a*, b*; reflectivity and opacity are made.
Color Measurements The initial and final color measurements of porcine or in-vivo human skin are made with a Hunter Lab spectracolormeter using a 0° light source and 45° detector geometry. The spectracolormeter is calibrated with the appropriate black and white standards. Measurements are made before and after the wash treatment. Three measurements are made each time and averaged. The values obtained are L, a*, b*, which come from the La*b ~ color space representation.
Opacity Determination The opacity of the skin treated by the cleansing composition can be derive d from the hunter Lab color measurements. The opacity contrast value is calculated from the delta L (which is the change in whiteness after deposition) divided by 60 (which is the difference in L value of the skin and a pure white color).
Reflectance o r Radiance Determination The initial and ffi nal reflectance/radiance measurement of porcine or in-viva human skin is made with a glossmeter before and after treatment with the cleansing composition.
The glossmeter is first set with both the detector and light source at 85° from normal. Then the glossmeter is calibrated with an appropriat a reflection standard. Measurements are made before and after application and rinsing off of the cleansing composition and the percent difference calculated.
Since a noticeabl a change in the skin when treated with the inventive composition may provide only scattered areas of skin appearance enhancement (such as point sparkle, glitter, etc.) instead of a continuous change over a wider expanse of the skin better suited to instrumental analysis using the glossmeter etc; for the purposes of defining the level of skin appearance change required to be shown for the inventive composition, a "yes" result in either the Tile method, the Consumer method, the Hand wash (lab) method, or any combination thereof is to be considered equivalent to at least a 5 o change in reflectivity when the inventive cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol.
In-viva Glitter C aunt Glitter count is a useful indicator regarding deposition but must be supplemented with other visual appearance methods to establish whether a sufficient change in visual appearance exists.
Method Wash a 5 cm by 10 cm sect ion of an inside forearm of a human panelist with the cleansing composition for 1 to 2 minutes with "normal" rubbing and rinse for 1/2 minute with 45°C tap water. Let air dry for 20 min (no wiping) at 25°C. Then, under an intense light source or sunlight, count the number of sparkles seen in the washed area. The minimum number of sparkles counted consider ed for a 'good" deposition is 2.
The results are compared to a control consisting of the surfactant system and dei onized water alone. The glitter count of the control is zero (i.e. no observable deposition).
Cone and Plate Viscosity Measurement Scope This method covers the measurement of the viscosity of the isotropic phase cleansing composition.
Apparatus Brookfield Cone and Plate DV-II+ Viscometer.
Spindle 541.
Procedure 1. Turn on Water Bath attached to the sample cup of the viscometer. Make sur a that it is set for 25°C. Allow temperature readout t o stabilize at 25°C before proceeding.
2. With the power to the ~riscometer off, remove the spindle (S41) by turning count erclockwise.
3. Turn the power on and press any key as requested to autozero the viscomete r.
4. When the autozero function is complete, replace the spindle (turning clockwise) and press any key.
5. Attach the sample cup. Using the up/down arrow keys, slowly change the spee d to 10 rpm and press the SET
SPEED key. Use the SELECT DISPLAY key so that the display is in o mode.' 6. Turn the motor on. If the display jumps to 0.4 0 or higher or will not set t le to 0 ~0.1 0, turn the adjustment ring clockwise until it does.
7. Rotate the adjustment ring counterclockwise until the reading is fluctuating between 0.0 and 1.0 0. The fluctuation must occur approximately every 6 seconds.
8. Turn the adjustment ring clockwise exactly the width of one division from the setting reached in step 7.
9. Turn the motor off. Using the up/down arrow keys, slowly change the speed to 0.5 rpm and press the SET
SPEED key. Use the SELECT DISPLAY so that the display is in cP.
10. Place 2 ~ O.lg of product to be measured into the sample cup. Attach the cup to the viscometer.
11. Allow the product to remain in the cup with the motor OFF for 2 minutes.
12. Turn the motor ON and allow the spindle to turn for 2 minutes before noting the reading on the display.
T- bar Viscosity Measurement Scope Th is method covers the measurement of the viscosity of the ordered liquid crystalline cleansing composition.
Apparatus Br ookfield RVT Viscometer with Helipath Accessory.
Clzuck, weight and closer assembly for T-bar attachment.
T-bar Spindle A.
PL astic cups diameter greater than 2.5 inches.
n~.~.....~"~.~
1. Verify that the viscometer and the helipath stand are level by referring to the bubble levels on the back of the instrument.
2. Connect the chuck/closer/weight assembly to the Viscometer. (Note the left-hand coupling threads).
3. Clean Spindle A with deionized water and pat dry with a Kimwipe sheet. Slide the spindle in the closer and tighten.
4. Set the rotational speed at 0.5 RPM. In case of a digital viscometer (DV) select the o mode and press autozero with the motor switch on.
5. Place the product in a plastic cup with inner diameter of greater than 2.5 inches. The height of the product in the cup should be at least 3 inches. The temperature of the product should be 25°C.
6. Lower the spindle into the product (~1/4 inches). Set the adjustable stops of the helipath stand so that the spindle does not touch the bottom of the plastic cup or come out of the sample.
7. Start the viscometer and allow the dial to make one or two revolutions before turning on the Helipath stand.
Note the dial reading as the helipath stand passes the middle of its downward traverse.
8. Multiply the dial reading biz a factor of 4,000 and report the viscosity reading in cps.
While this invention has been described with respect to particular embodiments thereof, it is apparent that numerous other forms and modifications o ~ the invention will be obvious to those skilled in the art. The appended claims and this invention generally sh~uld be construed to cover all such obvious forms and modifications which are within the true spirit and scope of the present invention.
Claims (20)
1. ~A liquid cleansing composition comprising:
(a) 1 % to 35 wt. % of surfactant(s) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereof;
(b) 0.1 % to 10 % of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by one or more skin evaluation methods selected from Tile evaluation method, Hand wash (consumer evaluation) method, Hand wash (lab evaluation) method, or a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 % change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol.
(a) 1 % to 35 wt. % of surfactant(s) selected from an anionic, nonionic, amphoteric or cationic surfactant or mixtures thereof;
(b) 0.1 % to 10 % of a cationic polymer; and, (c) an effective concentration of a solid particulate optical modifier for exhibiting a specific set of optical properties on skin characterized by one or more skin evaluation methods selected from Tile evaluation method, Hand wash (consumer evaluation) method, Hand wash (lab evaluation) method, or a set of Tristimulus Color Values Z, a*, and b*; a reflectivity change, and an opacity change, that provides at least a 5 % change in at least one of the specific optical properties when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol.
2. ~A composition according to claim 1 further comprising:
(a) a thickening agent;
(b) wherein the viscosity of the cleansing composition is in the range of 1,000 to 300,000 cps, preferably 5,000 to 50,000 cps @ 1/sec shear rate at 25°C using the Cone and Plate method; and, (c) wherein the cleansing composition is isotropic.
(a) a thickening agent;
(b) wherein the viscosity of the cleansing composition is in the range of 1,000 to 300,000 cps, preferably 5,000 to 50,000 cps @ 1/sec shear rate at 25°C using the Cone and Plate method; and, (c) wherein the cleansing composition is isotropic.
3. ~A composition according to claim 1 or claim 2 further comprising:
(a) 3 % to 30 % by weight of a surfactant system including at least one surfactant selected from an anionic, amphoteric, cationic and nonionic surfactant and mixtures thereof, wherein at least one anionic surfactant must be present;
(b) 0.1 % to 15 % by wt. of an ordered liquid crystalline phase a inducing structurant for inducing an ordered liquid crystalline phase in said cleansing composition; preferably wherein the ordered liquid crystalline phase inducing structurant is selected from a C8 to C24 alkenyl or branched alkyl fatty acid or ester thereof, a C8 to C24 alkenyl or branched alkyl alcohol or ether thereof, a C5 to C14 linear alkyl fatty acid, trihydroxystearin, or derivatives or mixtures thereof; more preferably wherein the ordered liquid crystalline phase inducing structurant is selected from lauric acid, oleic acid, palm kernel acid, palm fatty acid, coconut acid, isostearic acid, or derivatives or mixtures thereof; and still more preferably where in the ordered liquid crystalline phase has lamellar structure;
(c) wherein the ordered liquid crystalline phase composition has a viscosity of 40,000 to 300,000 cps at 25°C as measured via the T-bar method; and (d) wherein said ordered liquid crystalline phase composition contains less than 0.025 % by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and an average molecular weight of from 1,000 to 5,000,000.
(a) 3 % to 30 % by weight of a surfactant system including at least one surfactant selected from an anionic, amphoteric, cationic and nonionic surfactant and mixtures thereof, wherein at least one anionic surfactant must be present;
(b) 0.1 % to 15 % by wt. of an ordered liquid crystalline phase a inducing structurant for inducing an ordered liquid crystalline phase in said cleansing composition; preferably wherein the ordered liquid crystalline phase inducing structurant is selected from a C8 to C24 alkenyl or branched alkyl fatty acid or ester thereof, a C8 to C24 alkenyl or branched alkyl alcohol or ether thereof, a C5 to C14 linear alkyl fatty acid, trihydroxystearin, or derivatives or mixtures thereof; more preferably wherein the ordered liquid crystalline phase inducing structurant is selected from lauric acid, oleic acid, palm kernel acid, palm fatty acid, coconut acid, isostearic acid, or derivatives or mixtures thereof; and still more preferably where in the ordered liquid crystalline phase has lamellar structure;
(c) wherein the ordered liquid crystalline phase composition has a viscosity of 40,000 to 300,000 cps at 25°C as measured via the T-bar method; and (d) wherein said ordered liquid crystalline phase composition contains less than 0.025 % by weight of an organic, non-crosslinked, cationic homopolymer or copolymer having a cationic charge density of from 2 meq/gm to 10 meq/gm and an average molecular weight of from 1,000 to 5,000,000.
4. A composition according to any one of the preceding claims wherein the visual attribute targeted by the optical modifier is selected from skin shine, skin color or skin optical uniformity, and combinations thereof.
5. A composition according to claim 4 wherein the change in L value is in the range from 0 to ~10, the reflectance change is in the range from 0 to ~300 %, and the change in opacity is in the range from 0 to ~20 % with the proviso that the change in L value, reflectance change and opacity change are not all zero so as to provide noticeable skin shine when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol; preferably wherein greater than 10 % by wt. of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) ~the exterior surface has a refractive index of 1.8 to 4.0;
ii) ~the geometry is platy, cylindrical or a blend thereof; and iii) ~the specific dimensions are 10 to 200 µm average diameter in the case of a platy particle, or 10 to 200 µm in average length and 0.5 to 5.0 µm in average diameter in the case of a cylindrical particle.
i) ~the exterior surface has a refractive index of 1.8 to 4.0;
ii) ~the geometry is platy, cylindrical or a blend thereof; and iii) ~the specific dimensions are 10 to 200 µm average diameter in the case of a platy particle, or 10 to 200 µm in average length and 0.5 to 5.0 µm in average diameter in the case of a cylindrical particle.
6. A composition according to claim 4 wherein the change in Z value is in t he range from 0 to ~10, the change in the a* value is in the range from 0 to ~10, the change in the b* value is in the range from 0 to ~10, the change in opacity is i n the range from 0 to ~50 %, and the reflectance change is within the normal skin reflectivity range of +10 %, with the proviso that the change in L value, b* and opacity change are not all zero so as to provide noticeable skin lightening or color change when said cleansing composition is applied to skin and the n rinsed off using the In-vitro Visual Assessment Protocol; preferably wherein greater than 10 % by wt. of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 4.0;
ii) the geometry is spheroidal, platy or a blend thereof;
iii) the specific dimensions are 1 to 30µm average diameter in the case of a platy particle, or 0.1 to 1 µm in average diameter in the case of a spheroidal particle; and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
i) the exterior surface has a refractive index of 1.3 to 4.0;
ii) the geometry is spheroidal, platy or a blend thereof;
iii) the specific dimensions are 1 to 30µm average diameter in the case of a platy particle, or 0.1 to 1 µm in average diameter in the case of a spheroidal particle; and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
7. The composition according to claim 4 wherein the change in Z value is in the range from 0 to ~5, the reflectance change is in the range from 0 to ~100 %, the change in opacity is in the range from 0 to ~50 %, and the change in a* and b* are within normal skin color range of ~10 %
for each of a* or b*, with the proviso that the change in L value, reflectance change and opacity change are not all zero so as to provide noticeable skin optical uniformity change when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol; preferably wherein greater than 10 o by wt. of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 2.0 ii) the geometry is spheroidal, platy, cylindrical or a blend thereof iii) the specific dimensions are 0.1 to 200 µm in average diameter in the case of a spheroidal particle, 1 to 10 um average diameter in the case of a platy particle, or 1 to 10 µm in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle, and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
for each of a* or b*, with the proviso that the change in L value, reflectance change and opacity change are not all zero so as to provide noticeable skin optical uniformity change when said cleansing composition is applied to skin and then rinsed off using the In-vitro Visual Assessment Protocol; preferably wherein greater than 10 o by wt. of the particulate optical modifier is further defined by an exterior surface refractive index, geometry, and specific dimensions wherein:
i) the exterior surface has a refractive index of 1.3 to 2.0 ii) the geometry is spheroidal, platy, cylindrical or a blend thereof iii) the specific dimensions are 0.1 to 200 µm in average diameter in the case of a spheroidal particle, 1 to 10 um average diameter in the case of a platy particle, or 1 to 10 µm in average length and 0.5 to 5.0 um in average diameter in the case of a cylindrical particle, and iv) optionally having fluorescence color, absorption color, interference color or a combination thereof.
8. The composition according to any of claims 1 to 4 wherein the particulate optical modifier is composed predominately of platy particles further defined by having an average plate diameter of 10 µm to 200 µm and a refractive index of at least 1.8; and more preferably wherein t he particulate optical modifier contains a surface modification selected from amino acids, proteins, fatty acids, lipids, phospholipids (lecithin), anionic and/or cationic oligomers/polymers or blends or derivatives thereof to enhance the deposition of the optical modifier on to the skin.
9. A composition according to any preceding claim wherein the cationic polymer has a charge density of at least 0.7 Meq/g; preferably wherein the cationic polymer is selected from Merquat® 100 or 2200, Jaguar® C17 or C13S, Salcare® Supre 7, SC10, or SC30; Gafquat ® HS100 or 755, and Luviquat® FC370, FC550, HM552 or FC905; or blends thereof.
10. A composition according to any preceding claim wherein the composition contains an anionic surfactant;
preferably wherein the anionic surfactant is selected from a C8-C16 alkyl sulfate and/or alkyl ether sulfates, fatty aci d soaps, taurates, sulfosuccinates, glycinates, sarcosinates or blends thereof and the amphoteric surfactant is selected from amphoacetates, betaines and amidoalkyl betaines or derivatives or blends thereof;
and the ratio of anionic surfactant to a surfactant that has a positive charge at a pH of 6.5 or below is in the range of 15:1 to 1:2; more preferably wherein the surfactant with the positive charge is an amphoteric surfactant; and still more preferably wherein the amphoteric.surfactant is selected from betaine, alkylamidopropyl betaine, sulphobetaine, amphoacetate or blends thereof.
preferably wherein the anionic surfactant is selected from a C8-C16 alkyl sulfate and/or alkyl ether sulfates, fatty aci d soaps, taurates, sulfosuccinates, glycinates, sarcosinates or blends thereof and the amphoteric surfactant is selected from amphoacetates, betaines and amidoalkyl betaines or derivatives or blends thereof;
and the ratio of anionic surfactant to a surfactant that has a positive charge at a pH of 6.5 or below is in the range of 15:1 to 1:2; more preferably wherein the surfactant with the positive charge is an amphoteric surfactant; and still more preferably wherein the amphoteric.surfactant is selected from betaine, alkylamidopropyl betaine, sulphobetaine, amphoacetate or blends thereof.
11. A composition according to any one of the preceding claims further comprising an emollient having a weight average emollient particle size in the range of 1 to 500 microns; preferably wherein the composition contains less than 10 % by wt. of hydrophobic emollient(s).
12. A composition according to any one of the preceding claims further comprising greater than 30 % by weight water.
13. A composition according to any one of the preceding claims wherein the solid particulate optical modifier has an average diameter of at least 30 microns.
14. A composition according to any one of the preceding claims wherein the solid particulate optical modifier is present in a minimum concentration of at least 0.2 % by wt.
15. A composition according to any one of claims 2 to 14 wherein the thickening agent is selected from polyacrylates; silica, natural and synthetic waxes;
aluminum silicate; lanolin derivatives; C8 to C20 fatty alcohols polyethylene copolymers; polyammonium carboxylates; sucrose esters; hydrophobic clays;
petrolatum; hydrotalcites; cellulose derivatives, polysaccharide derivatives, or derivatives and mixtures thereof .
aluminum silicate; lanolin derivatives; C8 to C20 fatty alcohols polyethylene copolymers; polyammonium carboxylates; sucrose esters; hydrophobic clays;
petrolatum; hydrotalcites; cellulose derivatives, polysaccharide derivatives, or derivatives and mixtures thereof .
1C. A composition according to any one of claims 2 to 15 wherein the composition is structured with a structurant selected from swelling clays; cross-linked polyacrylates; acrylate homopolymers and copolymers;
polyvinylpyrrolidone homopolymers and copolymers;
polyethylene imines; inorganic salts; sucrose esters, gellants or blends and derivatives thereof.
polyvinylpyrrolidone homopolymers and copolymers;
polyethylene imines; inorganic salts; sucrose esters, gellants or blends and derivatives thereof.
17. A composition according to any one of claims 2 to 16 wherein less than 50 % by wt. of the solid particulate optical modifier is suspended in an oil.
18. A composition according to any one of the preceding claims having at least 7 wt %; preferably 10 to 25 wt %
of the surfactant.
of the surfactant.
19. The composition according to any one of the preceding claims wherein the particulate optical modifier is selected from organic pigments, inorganic pigments, polymers, titanium oxide, zinc oxide, colored iron oxide, chromium oxide/hydroxide/hydrate, alumina, silica, zirconia, barium sulfate, silicates, polyethylene, polypropylene, nylon, ultramarine, alkaline earth carbonates, talc, sericite, mica, synthetic mica, polymers, platy substrate coated with organic and inorganic materials, bismuth oxychloride, barium sulfate, or blends and physical aggregates thereof; preferably wherein the particulate optical modifier possesses color generated through fluorescence, adsorption, iridescence or a combination thereof.
20. A method of depositing a solid particulate optical modifier onto the skin from a liquid cleansing composition according to any of the preceeding claims, or a blend thereof, comprising the steps of:
(a) providing said solid particulate optical modifier in said cleansing composition;
(b) applying said cleansing composition to the skin or hair; and (c) rinsing off said cleansing composition.
(a) providing said solid particulate optical modifier in said cleansing composition;
(b) applying said cleansing composition to the skin or hair; and (c) rinsing off said cleansing composition.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/814,064 US6906015B1 (en) | 2004-03-31 | 2004-03-31 | Ordered liquid crystalline cleansing composition with particulate optical modifiers |
| US10/814,880 US7202199B2 (en) | 2004-03-31 | 2004-03-31 | Isotropic cleansing composition with particulate optical modifiers |
| US10/814,064 | 2004-03-31 | ||
| US10/814,880 | 2004-03-31 | ||
| PCT/EP2005/003243 WO2005094781A1 (en) | 2004-03-31 | 2005-03-23 | Liquid cleansing composition with particulate optical modifiers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2561501A1 true CA2561501A1 (en) | 2005-10-13 |
| CA2561501C CA2561501C (en) | 2013-05-28 |
Family
ID=34962923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2561501A Expired - Fee Related CA2561501C (en) | 2004-03-31 | 2005-03-23 | Liquid cleansing composition with particulate optical modifiers |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2007530621A (en) |
| KR (1) | KR20070001210A (en) |
| AR (1) | AR048357A1 (en) |
| BR (1) | BRPI0508763A (en) |
| CA (1) | CA2561501C (en) |
| MY (1) | MY141046A (en) |
| WO (1) | WO2005094781A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0722550D0 (en) | 2007-11-16 | 2007-12-27 | Innospec Ltd | Composition |
| US8017566B2 (en) | 2009-11-13 | 2011-09-13 | Conopco, Inc. | Liquid personal cleansing composition |
| CN103210030B (en) | 2010-11-23 | 2015-07-01 | 荷兰联合利华有限公司 | Composite particles and compositions with composite particles |
| CZ305528B6 (en) * | 2013-10-18 | 2015-11-18 | Ústav Fyzikální Chemie J. Heyrovského Akademie Věd České Republiky, V. V. I. | Cleaning mixture for removing hydrophobic protective coatings based on organosilicon polymers |
| JP6968699B2 (en) * | 2015-03-24 | 2021-11-17 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | Effervescent compositions, aerosol products, and their use to improve the sensory benefits of the skin |
| CN115100400B (en) * | 2022-07-27 | 2025-09-16 | 深圳思谋信息科技有限公司 | Lens film color measuring method, system, computer equipment and storage medium |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3580853A (en) * | 1967-09-27 | 1971-05-25 | Procter & Gamble | Detergent compositions containing particle deposition enhancing agents |
| PL186858B1 (en) * | 1995-08-07 | 2004-03-31 | Unilever Nv | Liquid washing up composition containing a soluble agent capable to cause formation of structure-giving lamellar phase |
| US5842237A (en) * | 1996-02-15 | 1998-12-01 | Lotecon, Llc | Convertible bed/chair with waste disposal |
| GB9827224D0 (en) * | 1998-12-10 | 1999-02-03 | Unilever Plc | Washing compositions |
| US6451300B1 (en) * | 1999-05-03 | 2002-09-17 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers |
| JP2001335442A (en) * | 2000-05-30 | 2001-12-04 | Shiseido Co Ltd | Detergent composition |
| US6797683B2 (en) * | 2002-03-04 | 2004-09-28 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Ordered liquid crystalline cleansing composition with benefit agent particles |
| JP2004107319A (en) * | 2002-07-22 | 2004-04-08 | Kao Corp | Skin cleansing composition |
-
2005
- 2005-03-23 KR KR1020067020452A patent/KR20070001210A/en not_active Ceased
- 2005-03-23 JP JP2007505476A patent/JP2007530621A/en active Pending
- 2005-03-23 CA CA2561501A patent/CA2561501C/en not_active Expired - Fee Related
- 2005-03-23 BR BRPI0508763-5A patent/BRPI0508763A/en not_active Application Discontinuation
- 2005-03-23 WO PCT/EP2005/003243 patent/WO2005094781A1/en active Application Filing
- 2005-03-29 MY MYPI20051374A patent/MY141046A/en unknown
- 2005-03-31 AR ARP050101265A patent/AR048357A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AR048357A1 (en) | 2006-04-19 |
| KR20070001210A (en) | 2007-01-03 |
| JP2007530621A (en) | 2007-11-01 |
| BRPI0508763A (en) | 2007-08-28 |
| WO2005094781A8 (en) | 2005-12-15 |
| MY141046A (en) | 2010-02-25 |
| CA2561501C (en) | 2013-05-28 |
| WO2005094781A1 (en) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7202199B2 (en) | Isotropic cleansing composition with particulate optical modifiers | |
| US6906015B1 (en) | Ordered liquid crystalline cleansing composition with particulate optical modifiers | |
| EP2928447B1 (en) | Concentrated lamellar liquid personal cleansing composition | |
| AU2006215824B2 (en) | Liquid cleansing composition with unique sensory properties | |
| US8017566B2 (en) | Liquid personal cleansing composition | |
| US20080081776A1 (en) | Mild foaming personal cleansing composition with high levels of hydrocarbon wax and oil emollients | |
| US20060094635A1 (en) | Aqueous cleansing composition with gel flakes | |
| EP3621582B1 (en) | Liquid personal cleansing composition | |
| WO2007017121A1 (en) | Liquid cleansing composition | |
| EP3669860B1 (en) | Liquid personal cleansing composition | |
| MX2008015964A (en) | Personal cleansing composition thickened by dilution. | |
| CA2561501C (en) | Liquid cleansing composition with particulate optical modifiers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210323 |